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Abbreviation list 
 
aa   amino acid 
ABIN   A20-binding inhibitor of NF-κB    
AP-1   Activator protein 1 
APCs   Antigen presenting cells 
ASC   Apoptosis-associated Speck-Like protein containing a CARD 
ASK   Apoptosis Signal-regulating Kinase 1 
ATF3   Activating transcription factor 3 
BiFC   Bimolecular Fluorescence Complementation 
BIR   Baculoviral Inhibitor of apoptosis Repeats 
CARD   Caspase Recruitment Domain 
CD   Clusters of Differentiation 
CRP   C-reactive protein 
DAG   Diacylglycerol 
DAI   DNA-dependent activator of IFN-regulatory factors 
DAMPs  Danger-Associated Molecular Patterns 
DAP   meso-diaminopimelic acid 
DC   Dendritic Cell 
DD   Death Domain 
DNA   Deoxyribonucleic Acid 
ds   double-stranded 
ECM   Extracellular Matrix 
EMCV  Encephalomyocarditis Virus 
ERK   Extracellular signal-regulated Protein Kinase 
FADD   Fas receptor associated death domain 
Fliih   Flightless I Homolog 
FRET   Fluorescence Resonance Energy Transfer 
GPCR  G-protein coupled receptor 
HBV   Hepatitis B Virus 
HCMV  Human Cytomegalovirus 
HCV   Hepatitis C Virus 
HEK   Human Embryonic Kidney 
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HEV   High Endothelial Venule 
HIV   Human Immunodeficiency Virus 
HMGB1  High-Mobility Group Box 1 
HSP   Heat Shock Protein 
HSV   Herpes Simplex Virus 
ICE   IL-1β converting enzyme 
IFN   Interferon 
Ig   Immunoglobulin 
IκB   Inhibitor of κB 
IKK    IκB kinase 
IL   Interleukin 
IL-1RAP  Interleukin-1 Receptor Accessory Protein 
IPAF   ICE protease activating factor 
IPS-I   Interferon Promoter Stimulator I 
IRAK   IL-1 Receptor-Associated Kinase 
IRF   Interferon Regulatory Factor 
ISRE   Interferon-stimulated Response Element 
ITAM   Immunoreceptor Tyrosine-based Activation Motif 
JAK   Janus Kinase  
LBP   LPS-binding protein 
LCMV   Lymphocytic Choriomeningitis Virus 
LPS   Lipopolysaccharide 
LRR   Leucine-Rich Repeat 
LTA   Lipoteichoic Acid 
Mal   MyD88 Adaptor-Like  
MALP-2  Macrophage-Activating Lipopeptide-2kDa 
MAPK(KK)  Mitogen Activated Protein Kinase (Kinase Kinase) 
MAPPIT  Mammalian Protein-Protein Interaction Trap 
MASP   MBL-associated serine proteases 
MBL   Mannan-binding lectin 
MCMV  Murine Cytomegalovirus 
Mda5   Melanoma differentiation associated gene 5 
MDP   Muramyl Dipeptide 
MEF   Mouse Embryonic Fibroblast 
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MEK(K)  MAPK-ERK Kinase (Kinase) 
MHC   Major Histocompatibility Complex 
MKK   MAPK Kinase 
MSR   Macrophage scavenger receptor 
MyD88  Myeloid Differentiation primary response gene 88 
MyD88s  MyD88 short 
NALP   NACHT-, LRR-, and pyrin-domain-containing proteins 
NAP1   NF-κB-activating kinase-Associated Protein 1    
NDV   Newcastle Disease Virus 
NK    Natural Killer 
NLR   NOD-Like Receptor 
NOD   nucleotide-binding oligomerisation domain 
PAMP   Pathogen-Associated Molecular Pattern 
pDC   plasmacytoid DC 
PG   Peptidoglycan 
Pin1   Peptidyl-prolyl-isomerase 
PKC   Protein kinase C 
PRR   Pathogen Recognition Receptor 
RHIM   Rip Homotypic Interacting Protein 
RIG-I   Retinoic-acid-Inducible protein I 
RIP1   Receptor-Interacting Protein 1 
RLR   RIG-I-Like Receptor 
RNA   Ribonucleic Acid 
RP105  Radioprotective 105 
RSV   Respiratory syncytial virus 
SAP   serum ameyloid protein 
Sarm   Sterile alpha and HEAT-Armadillo motifs containing protein 
SH2   Src Homology 2 
SHP-2  SH-2 containing protein tyrosine phosphatase-2 
SIGIRR  Single immunoglobulin IL-1R-related protein 
SOCS   Suppressor of cytokine signalling 
SR-A   Scavenger receptors type A   
ss   single-stranded 
STAT   Signal Transducer and Activator of Transcription 
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SYK   Spleen Tyrosine Kinase 
TAB   TAK1-binding Protein 
TAK1   Transforming growth factor-β-activated Kinase 1 
TANK   TRAF-family-member-associated NF-κB activator 
TAP   Tandem Affinity Purification 
TBK1   TANK-binding Kinase 1 
TGF-β  Transforming Growth Factor β 
Th   T-helper 
TIR   Toll IL-1 Receptor 
TLR   Toll-Like Receptor 
TNF   Tumor Necrosis Factor 
TNFR   Tumor Necrosis Factor Receptor 
Tollip   Toll-interacting protein 
TPL2   Tumor progression locus 2 
TRAF   Tumor Necrosis Factor-associated factor 
TRAIL(-R)  TNF-related apoptosis-inducing ligand (receptor) 
Tram   Trif-related adapter molecule 
Trif   TIR-domain-containing adaptor inducing interferon 
Ubc 13  Ubiquitin-conjugating enzyme 13 
VEGF   Vascular Endothelial Growth Factor 
VSV   Vesicular Stomatitis Virus 
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Samenvatting 
 
Vertebraten bezitten een ingenieus verdedigingssysteem waarmee ze zich wapenen tegen 
het constante gevaar van invasieve pathogenen. Het immuunsysteem bij zoogdieren kan 
onderverdeeld worden in een adaptieve en een aangeboren respons. De adaptieve immuniteit is 
gebaseerd op clonale expansie van T and B lymphocyten die antigen-specifieke receptoren 
expresseren. Door deze clonale selectie en expansie is de adaptieve respons pas volledig 
operationeel drie tot vijf dagen na infectie. De aangeboren respons daarentegen vormt de 
eerstelijnsdefensie tegen pathogenen en is daarom essentieel om de infectie onder controle te 
houden tot de adaptieve respons geactiveerd wordt. De aangeboren immuniteit maakt gebruik 
van een gelimiteerde set aan pathogeen-herkennende receptoren waarvan de familie van de Toll-
Like receptoren (TLRs) de belangrijkste zijn. TLRs herkennen een brede waaier aan bacteriële en 
virale structuren zoals lipopolysaccharide, dsRNA of bacterieel DNA. Deze structuren worden 
vaak pathogeen-geassocieerde moleculaire patronen of PAMPs genoemd. PAMPs zijn essentieel 
voor het overleven en de replicatie van deze pathogenen en zijn daarom onveranderd gebleven 
doorheen de evolutie. Herkenning van een pathogen door TLRs leidt tot de productie van pro-
inflammatoire cytokines. Deze cytokines activeren de aangeboren immuuncellen zoals 
macrofagen en neutrofielen. De TLRs zijn bovendien ook betrokken bij de activatie en modulatie 
van de daaropvolgende adaptieve immuunrespons. Echter, ongepaste en overmatige activatie 
van de TLR signaalweg leidt tot excessieve inflammatie wat vaak enorm schadelijk is. Daarom is 
de TLR signaalweg strikt gereguleerd. Verscheidene modulatoren zijn beschreven die ofwel 
interfereren in ligand binding, ofwel de receptorexpressie beïnvloeden ofwel de intracellulaire 
signaalweg moduleren. 
Dit werk richt zich voornamelijk op de initiële stappen van de TLR signaalweg. Daarbij zijn 
vier adaptor molecules betrokken: MyD88, Mal, Trif and Tram. Verschillende TLRs gebruiken 
verschillende combinaties van adaptoren, wat gedeeltelijk de ligand specifieke respons kan 
verklaren. Door gebruik te maken van MAPPIT (Mammalian Protein-Protein Interaction Trap), 
een twee-hybride methode die in ons laboratorium werd ontwikkeld, creëerden we een TLR-
adaptor interactiemap. Bovendien toonden we aan dat Mal een brugfunctie vervult in TLR2 en 
TLR4 signalisatie, door MyD88 naar de geactiveerde receptor te derigeren. We identificeerden 
CIS, een lid van de SOCS proteïne familie, als een mogelijke regulator van de MyD88-
afhankelijke signaalweg en toonden aan dat de bindingsmodaliteiten van CIS verschilden tussen 
receptor en MyD88 interactie. 
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Summary 
 
Vertebrates developed an ingenious defence system, by which they counteract the 
continuous peril of invading pathogens. This mammalian immune system can be divided in an 
innate and an adaptive branch. Adaptive immunity relies on clonally expanded T and B 
lymphocytes expressing antigen-specific receptors. However, due to this clonal selection and 
expansion, the adaptive response is only fully functional three to five days after infection. The 
innate immune response, on the other hand, provides a first line of defence against pathogens 
and therefore is essential in containing the infection until the adaptive response is initiated. The 
innate immune system makes use of a distinct set of germ-line encoded pathogen-recognition 
receptors (PRRs) of which the family of Toll-Like receptors (TLRs) form the major constituent. 
TLRs recognize a wide spectrum of bacterial and viral structures including bacterial 
lipopolysaccharide, dsRNA or bacterial DNA. These structures are referred to as pathogen-
associated molecular patterns (PAMPs). PAMPs are essential for the survival and replication of 
these pathogens and therefore are conserved throughout evolution. Pathogen recognition by 
TLRs ultimately leads to the production of pro-inflammatory cytokines, essential for the activation 
of innate immune cells, like macrophages and neutrophils. Moreover, TLRs are involved in the 
activation and modulation of the subsequent adaptive response. However, aberrant activation of 
TLR signalling leads to excessive inflammation which is extremely harmful for the host. Therefore 
this signalling pathway is tightly controlled by numerous regulators, which interfere in TLR 
signalling either by inhibiting ligand binding, by downregulation of receptor expression or by 
interference of downstream signalling. 
This work focuses on the initial steps of TLR signalling, mediated by four adaptor molecules: 
MyD88, Mal, Trif and Tram. Selective usage of these adaptors by different TLRs in part accounts 
for ligand specific responses. Using MAPPIT (Mammalian Protein-Protein Interaction Trap), a 
mammalian two-hybrid method developed in our laboratory, we generated a TLR-adaptor 
interaction map. Moreover, we provided evidence that Mal acts as a bridging adaptor, linking 
MyD88 to TLR2 or TLR4. In addition, we identified CIS, a member of the SOCS protein family, as 
a possible regulator of MyD88-dependent signalling, and showed that the binding properties of 
CIS differ between cytokine receptor and MyD88 binding. 
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Résumé 
 
Les vertébrés ont développé un système de défense ingénieux, par lequel ils combattent 
les menaces continues des pathogènes envahissants. Ce système immunitaire mammifère peut 
être divisé en une branche innée et adaptative. L'immunité adaptative est basée sur l’expansion 
clonale des lymphocytes T et B qui expriment des récepteurs d’antigène spécifique. Mais en 
raison de cette sélection et expansion clonale, la réponse adaptative n’est fonctionnelle que trois 
à cinq jours après l’infection. D'autre part, l’immunité innée fournit une première ligne de défense 
contre les microbes pathogènes et est donc essentielle pour contrecarrer l'infection jusqu'à ce 
que la réponse adaptative soit induite. Le système immunitaire inné se sert d'un ensemble de 
récepteurs, appelés les Pattern-Recognition Receptors (PRRs) dont la famille de récepteurs Toll-
Like (TLRs) forment le composant principal. Les TLRs peuvent identifier une gamme étendue de 
structures bactériennes et virales comme le lipopolysaccharide bactérien, l’ARN double brin ou 
l'ADN bactérien. Ces structures sont appelées Pathogen-Associated Molecular Patterns (PAMPs) 
et elles sont cruciales pour la survie et la réplication de ces microbes pathogènes, et pour cela 
leurs structures ont été fort conservées à travers l'évolution. Finalement, l'identification de 
microbes pathogènes par les TLRs mène à la production de cytokines pro-inflammatoires qui 
sont essentielles dans l'activation des cellules immunitaires innées, comme les macrophages et 
les neutrophiles.   De plus, les TLRs sont aussi impliqués dans l'activation et la modulation de la 
réponse adaptative qui en suit. Cependant, une activation aberrante de la signalisation émanant 
des TLR mène à une inflammation excessive qui peut être extrêmement nocive pour l’hôte. Par 
conséquence, cette voie de signalisation est strictement contrôlé par de nombreux régulateurs 
interférant avec la cascade de signalisation des TLRs en empêchant l'interaction du ligand, en 
diminuant l’expression des récepteurs ou en interférant avec la signalisation en aval. 
Ce projet se focalise sur les premières étapes de la cascade de signalisation des TLRs, 
menés par quatre molécules adaptatrices: MyD88, Mal, Trif et Tram. L'emploie sélective de ces 
molécules adaptatrices par les différents TLRs contribue entre autre aux réponses spécifiques 
induites par les différents ligands. En utilisant MAPPIT (Mammalian Protein-Protein Interaction 
Trap), une méthode deux-hybride dans des cellules mammifères qui a été développée dans notre 
laboratoire, nous avons généré une carte d'interactions des TLRs et leurs molécules 
adaptatrices. Par ailleurs, nous avons fourni l'évidence que Mal agit en tant que molécule 
adaptatrice reliant MyD88 à TLR2 ou à TLR4. Finalement, nous avons identifié CIS, un membre 
de la famille de protéine des SOCS, comme régulateur potentiel de la cascade de signalisation 
dépendant de MyD88, et nous avons démontré que les caractéristiques des interactions de CIS 
diffèrent pour l’association avec les récepteurs des cytokines d’une part et l’interaction avec 
MyD88 d’une autre part. 
 
 
 
 - 14 -
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 - 15 -
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PART 1: Pathogen recognition receptors in 
innate immunity 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 - 16 -
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 - 17 -
CHAPTER 1: General introduction 
 
I. Introduction 
 
Since invading pathogenic micro-organisms are a continuous threat, vertebrates 
developed an ingenious defence system. This vertebrate immune system commonly 
is divided in an innate and an adaptive branch (Table 1).  The adaptive or acquired 
immune system is characterised by specificity and memory and is mediated by T and 
B lymphocytes. Each single lymphocyte expresses a structurally unique antigen 
receptor, resulting in a large and diverse population. This diversity is achieved by a 
process of gene rearrangement and should enable recognition of almost any antigen. 
Binding of a specific antigen to an individual lymphocyte, results in the activation and 
proliferation of the cell. This clonal selection and expansion is fundamental for a 
successful immune response. However, it is a time-consuming process, which 
generally takes three to five days, giving pathogens enough time to overwhelm the 
host.  
The innate immune response, on the other hand, provides an immediate 
response against pathogens and is essential in restraining the infection in the first 
couple of days. Next to containing infection, innate immunity activates and defines 
the nature of the subsequent adaptive responses by promoting antigen presentation 
and the production of co-stimulatory molecules and pro-inflammatory cytokines. 
Innate-induced pathogen clearance relies on efficient detection mediated by pattern-
recognition receptors (PRRs) (Janeway, Jr., 1989). These restricted sets of germ-line 
encoded receptors recognize highly conserved microbial structures like bacterial 
lipopolysaccharide (LPS), dsRNA or bacterial DNA, commonly referred to as 
Pathogen-Associated Molecular Patterns (PAMPs). These PAMPs are essential for 
the replication and viability of a broad range of pathogens. Since these PAMPs are 
restricted to micro-organisms and invariant throughout evolution, detection of these 
structures by PRRs provides an elegant way of discriminating between self and non-
self antigens and circumvents the need for a highly variant set of antigen-specific 
receptors. PRRs can be secreted in the bloodstream or expressed intracellularly or 
on the cell surface of innate immune cells like macrophages, neutrophils and 
dendritic cells. Their main functions include opsonisation, activation of the 
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complement system, mediating phagocytosis and induction of pro-inflammatory 
signalling pathways. 
 
 
   
 Innate immune system Adaptive immune system 
   
   
Receptors Fixed in genome Encoded in gene segments 
 Rearrangement is not necessary Rearrangement necessary 
   
   
Distribution Non-clonal Clonal 
 All cells of a class identical All cells of a class distinct 
   
   
Recognition Conserved molecular patterns Details of molecular structure 
   
   
Self vs non-self Perfect: selected over evolutionary time 
Imperfect: selected in individual 
somatic cells 
   
   
Action time Immediate activation of effectors Delayed activation of effectors 
   
   
Response Co-stimulatory molecules Clonal expansion or anergy 
 Type I IFN, IL-6, IL-12 IL-2, IL-4, IFN-γ 
   
 
Table 1: Characteristics of innate and adaptive immunity (adapted from Janeway, Jr. 
and Medzhitov, 2002) 
 
 
II.  Secreted and endocytic PRRs 
 
Some secreted PRRs, like Mannan-binding lectin (MBL), C-reactive protein 
(CRP), and the serum amyloid protein (SAP) are produced by the liver during the 
acute phase response following infection. MBL is a member of the collectin family, 
which is characterised by a collagenous domain linked to a lectin-domain. MBL 
recognizes carbohydrates of gram-positive and gram-negative bacteria as well as 
viral envelope proteins via its lectin domain (Fraser et al., 1998). MBL activates the 
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complement system by interaction with two serine proteases, MBL-associated serine 
proteases (MASP) 1 and 2, resulting in the activation of the lectin pathway of 
complement (Fig.1) (Thielens et al., 2002; Rossi et al., 2001). CRP and SAP are 
members of the pentraxin family and act as opsonins by interacting with 
phosphorylcholine and LPS (Garlanda et al., 2005). Moreover, these pentraxins can 
interact with C1q, leading to the activation of the classical complement pathway, 
normally activated by immune complexes (antibody-antigen complexes) (Fig.1) 
(Agrawal et al., 2001). Activation of these complement pathways leads to direct killing 
of pathogens, recruitment of inflammatory cells and phagocytosis of opsonised 
pathogens mediated by complement receptors expressed on myeloid cells (Gasque, 
2004). 
Next to these secreted PRRs, several cell-surface PRRs expressed on 
macrophages also mediate pathogen phagocytosis.  One such endocytic PRR, 
macrophage mannose receptor, is a C-lectin family member and senses mannose, 
fucose and N-acetyl glucosamine residues in the cell-wall of various pathogens, 
thereby inducing opsonin-independent phagocytosis. The scavenger receptor type A 
(SR-A) family forms another group of endocytic PRRs. SR-A member Macrophage 
scavenger receptor (MSR) recognizes a variety of polyanionic ligands, like LPS, 
dsRNA and Lipoteichoic Acid (LTA). Analysis of MSR-deficient mice revealed a key 
function for MSR in host defence as these mice were highly susceptible to Listeria 
monocytogenes, Staphylococcus aureus, herpes simplex virus (HSV) and malaria 
infections (Suzuki et al., 1997; Thomas et al., 2000). Another family member, 
MARCO, recognizes LPS and also mediates phagocytosis (Elomaa et al., 1995).   
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Fig.1: The lectin and classical 
complement pathway adapted 
from Medzhitov and Janeway, 
Jr., 2000.  Mannose-binding lectin 
recognizes carbohydrates on the 
bacterial cell surface. Ligand 
recognition leads to the activation 
of two associated serine 
proteases, MASP1 and MASP2, 
which cleave complement 
component C4 and C2. Next, 
cleavage products C4b and C2a 
form a C3 convertase, further 
activating the complement system 
by cleavage of C3. The classical 
complement pathway relies on 
C1q binding with antigen-antibody 
complexes, CRP or SAP, resulting 
in the activation of serine 
proteases C1r and C1s, which in 
analogy with MASP1 and MASP2 
cleave complement component C4 
and C2. Complement activation 
ultimately leads to the 
opsonisation of pathogens, the 
direct killing of pathogens and the 
recruitment of inflammatory cells.    
 
 
 
 
III.  Signalling PRRs 
 
For a long time it was known that some bacterial and viral structures, like bacterial 
LPS, peptidoglycan or viral double-stranded RNA, can activate the immune system. 
However, it took until the late nineties before their receptors could be identified. First, 
Lemaitre and Hoffman demonstrated that the Drosophila melanogaster protein Toll, 
known for its role in embryonic dorso-ventral patterning, is also an essential 
component of the immune response against the fungus Aspergillus fumigatus. The 
following year, the first human analogue of Drosophila Toll (human Toll), now known 
as Toll-Like receptor 4 (TLR4), was identified (Medzhitov et al., 1997). Finally, the 
observation that a single PÆH mutation in the TLR4 gene rendered the mouse strain 
 - 21 -
C3H/HeJ unresponsive to LPS triggering, highlighted the major role of this TLR in 
PAMP-based vertebrate innate immunity (Poltorak et al., 1998). At present 10 human 
and 13 murine TLRs are identified, detecting a wide spectrum of bacterial and viral 
PAMPs at the cell-surface or within phagocytic endosomes. 
Next to TLRs, an emerging group of other signalling PRR families were 
discovered, for example NOD-Like and RIG-I-Like receptors, that broadcast the 
presence of pathogens intracellularly, or dectin-1, a transmembranary receptor 
important in fungal defence (Fig.2).  The importance and function of all these 
signalling PRRs in innate immunity, as well as the synergy between different PRR 
families, will be discussed throughout this thesis.  
PRR signalling ultimately leads to the activation of transcription factors like NF-κB, 
AP-1 and interferon regulatory factors (IRFs) and concomitant gene induction of pro-
inflammatory cytokines, chemokines and co-stimulatory molecules (Hirotani et al., 
2005). As such, PRRs are crucial components of the innate immune system but are 
also involved in the activation and shaping of subsequent adaptive responses, which 
will be discussed in the following section. 
Triggering of RIG-Like receptors and a subset of TLRs leads to the production of 
type I interferons (IFNs), thereby inducing an antiviral state. Upon viral infection most 
cells produce type I IFNs but recently a subset of dendritic cells (DCs), plasmacytoid 
DCs, was shown to produce enormous amounts of these cytokines upon PRR 
stimulation (Cao and Liu, 2007). Therefore these ‘professional’ type I IFN-producing 
cells are crucial mediators of antiviral innate immune responses. IFN stimulation of 
target cells leads to the induction of a set of antiviral genes of which dsRNA-
dependent protein kinase PKR, 2’5’ oligoadenylate synthetase and MX proteins are 
the best-characterised examples (Levy and Garcia-Sastre, 2001). These proteins 
interfere in viral replication and induce apoptosis of the infected cells. Moreover, type 
I IFNs activate specific subsets of innate immune cells, like DCs (see below) and 
natural killer (NK) cells (Gidlund et al., 1978). These NK cells express receptors for 
major histocompatibility complex (MHC) class I, and are programmed to lyse cells 
lacking this MHC type I. Normal host cells are MHC class I positive, but its 
expression is often downregulated by viral infection. That way, a CD8+ cytotoxic T 
cell response is inhibited (see below), but makes the cell vulnerable to NK cell-
mediated lysis, a process often referred to as missing self recognition. In addition, 
type I IFNs enhance the expression of MHC type I, thereby promoting the afore 
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mentioned  adaptive CD8+ cytotoxic T cell response (Ehrlich et al., 1989). Next to 
their crucial role in innate immunity, these type I IFNs regulate adaptive T-cell 
responses, for instance biasing naive Th cells towards a Th1 response (see below) 
(Smith et al., 2005; Belardelli and Ferrantini, 2002). 
 
 
 
 
 
Fig.2:  Pattern Recognition Receptors in innate immunity; different receptors for 
different needs.  Innate immunity relies on the detection of evolutionary conserved 
pathogen structures (Pathogen-Associated Molecular Patterns or PAMPs) by so called 
Pathogen-Recognition Receptors (PRRs). Over the past years, a growing number of PRRs 
have been described: (A) Toll-Like receptors (TLRs) recognize diverse viral or bacterial 
products (LPS, flagellin, viral RNA, bacterial DNA) either in the extracellular lumen or in 
endosomal compartments. (B) RIG-I-Like receptors (RLRs), on the other hand, sense 
intracellular viral RNA, while (C) NOD-Like receptors (NLRs) respond to a multitude of 
PAMPs like peptidoglycan (PGN)–derived molecules and danger-associated molecular 
patterns or DAMPs. (D) Another transmembrane receptor, Dectin-1, ensures a potent 
immune reaction in response to fungal threat. (E) Finally, DNA-dependent activator of IFN-
regulatory factors (DAI) senses cytosolic DNA. Cellular responses induced by these 
receptors include the production of chemokines, co-stimulatory molecules and inflammatory 
cytokines, not only necessary for the activation of innate immune cells but also involved in 
the activation and shaping of the subsequent adaptive response.  
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PRR activation induces the production of a multitude of pro-inflammatory 
cytokines including interleukin-6 (IL-6), IL-12 and tumor necrosis factor (TNF)-α.  
IL-6 is produced by both innate and adaptive immune cells like T-lymphocytes, 
macrophages and monocytes. It exerts pleiotropic effects on different target cells like 
induction of acute phase response genes in hepatocytes, neutrophils activation, 
stimulation of B-cell proliferation and inhibition of regulatory T-cells (Treg) (see 
below) (Pasare and Medzhitov, 2003; Kopf et al., 1995; Borish et al., 1989).  
IL-12 is a heterodimeric cytokine generally produced by macrophages and DCs. It 
predominantly functions as IFN-γ-inducing factor on NK cells and T-cells. IFN-γ is a 
potent activator of macrophages, NK cells and DCs and biases naive T-cells towards 
a Th1 response. IL-12 also induces the differentiation of naive T-cells into Th1 cells 
and it potentiates the cytotoxic activity of cytotoxic T lymphocytes (CTLs) and NK 
cells (Trinchieri, 2003). 
One of the best-characterised cytokines induced by PRRs is TNF-α. It is produced 
by DCs, NK cells, macrophages and endothelial cells among others and is a key 
cytokine in inflammation. TNF-α was originally identified as a cytotoxic agent for 
certain tumor cells but over the years a broader role in immunity became apparent  
(Locksley et al., 2001; Aggarwal, 2003; Pfeffer, 2003). It induces pleiotropic effects 
including neutrophils and macrophage activation, promotion of vascular endothelial 
permeability, chemokines production and activation of the acute phase response. 
The functions of TNF-α are not restricted to modulation of immune responses as it 
can induce insulin resistance, fever and a hypermetabolic state. 
One of the major innate functions of PRR-induced chemokines, like RANTES, IP-
10 and MIP-1β, is attracting innate immune cells, like neutrophils, macrophages and 
monocytes to the site of infection, ensuring a potent innate response. However, 
chemokine function is not restricted to this chemotactic activity since chemokines and 
their receptors are also involved in multiple other immune processes like DC and T-
cell maturation and regulation of DCs, B-cell and T-cell migration (see below) (Rot 
and von Andrian, 2004). 
 
 
 
 
 
 - 24 -
IV.  Innate control of adaptive immunity through modulation of 
dendritic cell function 
 
 
Recent data reveal an essential link between innate and adaptive immune 
responses. PAMP recognition by PRRs is proven to be crucial for the initiation and 
orientation of adaptive immune responses. A key role in this process is played by 
DCs. Activated peripheral DCs migrate to the lymph nodes, where they present 
antigens on MHC molecules to the relevant T lymphocytes, thereby activating the 
latter cells in an antigen-specific manner. Depending on the type of MHC-antigen 
complex presented and on the subset of secreted cytokines and chemokines, DCs 
activate and induce differentiation of CD4+ Th1 lymphocytes (MHCII, IFN-γ/IL-
12/IFN-α/IFN-β), CD4+ Th2 lymphocytes (MHC class II, IL-4/IL-5) and CD8+ 
Cytotoxic T lymphocytes (MHC class I). This process requires phagocytosis of 
pathogens, upregulation of MHC molecules for efficient antigen presentation, 
induction of co-stimulatory molecules and cytokines and migration to lymphoid 
tissues. All of these processes were shown to be mediated by innate PRRs 
expressed on DCs.  Of all the PRRs expressed by DCs, including scavenger 
receptors, mannose receptors, NOD-Like receptors, RIG-I-Like receptors and TLRs, 
only the latter have been shown to be involved in this regulation, although other 
PRRs are expected to exhibit similar functions.  
The initial phagocytosis and subsequent antigen processing and presentation 
by DCs were shown to be TLR-dependent. Blander and Medzithov found that TLR 
activation by bacteria, but not by apoptotic cells, regulated phagocytosis at multiple 
steps including internalization and phagosome maturation (Blander and Medzhitov, 
2004). These authors also showed that the efficiency of presenting antigens from 
phagocytosed cargo is dependent on the presence and detection of TLR ligands 
within the cargo (Blander and Medzhitov, 2006). 
Next, DCs migrate to the lymph nodes, a process initiated by a switch of 
chemokine receptor expression. LPS-stimulation of immature DCs leads to the 
downregulation of chemokine receptors which respond to ligands found in 
inflammatory sites including CCR1, CCR5 and CCR6 whereas expression of CCR7, 
which responds to chemokines in lymphoic organs and thus induces DC migration, is 
upregulated (Sallusto et al., 1998; Dieu et al., 1998; Forster et al., 1999). 
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Once in the lymph nodes, DCs provide several signals to activate naive T-
cells. First, the specific T-cell receptor interacts with the peptide-MHC complex 
expressed on DCs. The second signal is based on TLR-induced expression of co-
stimulatory molecules like B7-1 (CD80) and B7-2 (CD86) on the DCs, which trigger 
CD28 on the T-cell. The third signal involves the abrogation of suppressive effects of 
Tregs. Additionally to the expression of co-stimulatory molecules, this subset of T 
lymphocytes maintains tolerance to self-antigens. However, DCs activated by 
pathogen recognition produce high amounts of IL-6, which acts on the antigen 
specific T cells thereby inhibiting the inhibitory effects of Tregs (Pasare and 
Medzhitov, 2003; Yang et al., 2004).  
Next, activated CD4+ T cells differentiate into Th1 or Th2 effector cells. This 
choice is in part based on cytokines expressed by DCs. TLR-activated DCs seem to 
bias naive T-cells towards a Th1 response, induced by the secretion of Th1 cytokines 
like IL-12 and IL-6 (Schnare et al., 2001). Accordingly, mice deficient in MyD88, a 
central adaptor in TLR signalling, exhibit severely impaired Th1 responses and 
instead support Th2 differentiation (Schnare et al., 2001; Kaisho et al., 2002). This 
Th1 response is consistent with the viral, fungal, prokaryotic or protozoan nature of 
the PAMPs recognized by TLRs. Th2 responses, on the other hand, are mounted 
upon infection with multicellular eukaryotes, which are recognized by an unknown 
sensor.    
Antigen presentation by dendritic cells can only lead to efficient adaptive 
responses when the antigen-specific T-cells are quickly transported from the blood 
stream into the lymph nodes. This lymphocyte entry is mediated by a structure called 
high endothelial venule (HEV). Maturation of the lymph nodes following infection is 
accompanied with the growth of these HEVs, which results in higher lymph node 
entry. This process is in part dependent on activated DCs as lymph node maturation 
was observed upon DC injection (MartIn-Fontecha et al., 2003). Moreover, depletion 
of these cells was shown to result in diminished numbers of lymphocytes in lymphoid 
tissues (Zammit et al., 2005). This lymph node maturation is induced by vascular 
endothelial growth factor (VEGF), produced upon DC-dependent recruitment of 
unknown blood-borne cells (Webster et al., 2006).   
 Together, these findings reveal a tight link between innate and adaptive 
responses, mediated by PRRs expressed on dendritic cells. Therefore, PRR 
signalling components are valuable therapeutic targets and TLR agonist as well as 
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TLR antagonists are already applied in antitumor and antiviral therapy, in treatment of 
allergic and autoimmune diseases and as vaccine adjuvants (see Chapter 4). 
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CHAPTER 2: Toll-Like Receptors 
 
 
II. Structure 
 
 
 
 
All thirteen mammalian Toll-Like receptors (TLR1-13) are type I 
transmembrane glycoproteins, comprised of extracellular Leucine-Rich Repeat (LRR) 
motifs, essential in ligand binding, a single α–helical transmembrane domain and a 
cytosolic Toll-IL-1R (‘TIR’) interaction domain, mediating receptor dimerisation and 
downstream signalling.  Toll-Like receptors recognize extremely diverse PAMPs (see 
below; Table 1), varying from dsRNA (TLR3), to lipopeptides (TLR2), flagellin (TLR5), 
and even small synthetic molecules (TLR7/8). Therefore, the TLR ectodomain, 
composed of 19-25 LRRs, is designed for highly variable molecule recognition.  The 
LRR motif consists of 24 amino acids (aa), characterised by a 
xL2xxL5xL7xxN10xφ12xxφ15xxxxF20xxL23x consensus motif (φ represents any 
hydrophobic aa, and x any aa) (Bell et al., 2003). Each LRR is composed of a short 
parallel β-sheet, an α-helix and a variable region. Initially, structural knowledge was 
based on the extracellular domain of TLR3, since it was the only resolved TLR-
ectodomain crystal structure (Choe et al., 2005; Bell et al., 2005). The extracellular 
domain of TLR3 forms a highly glycosylated horseshoe-shaped solenoid composed 
of 23 LRRs (Fig. 2A-B). The β-sheets of the LRRs form the inner or concave surface 
of the solenoid and the conserved hydrophobic residues form the core. These 
hydrophobic residues are N- and C-terminally shielded by cysteine-rich capping 
domains. LRR12, -14, -18 and -20 all exhibit insertions after residue 10 of the 
consensus motif, which could account for specific ligand recognition. Based upon the 
two independently solved crystal structures, models were setup identifying the 
dsRNA binding site of TLR3.  Additional data should give us more insight in the exact 
nature of ligand binding. Considering the highly glycosylated nature and overall 
negative charge of the concave surface, Chloe et al. proposed that binding of dsRNA 
occurs at the non-glycosylated convex side of TLR3. Basic residues herein facilitate 
binding. Based on the position of bound sulphate ions from the crystallisation 
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medium, which could mimic phosphates from the RNA nucleotide backbone, Bell and 
colleagues proposed three possible binding sites. Two binding sites map to the 
glycosylated concave surface, whereas the third is located in a shallow non-
glycosylated groove between the two insertions on LRRs 12 and 20 (Fig.2C). The 
latter binding site was further confirmed by mutational analysis (Bell et al., 2006). 
Additionally, two positively charged, non-glycosylated patches were described, 
greatly adding to ligand binding. Moreover, a recent mutagenesis study revealed that 
only 3 of the 23 LRRs are dispensable for TLR3 function and that 3 C-terminal LRRs 
(LRR20-22) are essential for ligand-induced receptor dimerisation and intracellular 
signal transmission (Takada et al., 2007). 
 
 
  
 
 
Fig.2 : TLR3 ectodomain (adapted from Bell et al., 2005).  (A)The extracellular domain 
of TLR3 forms a horseshoe-shaped solenoid composed of 23 LRR, stabilized by N- and 
C-terminal capping structures. (B) The concave surface of the TLR3 ectodomain is 
composed of parallel β-sheets originating from each LRR. (C) The unglycosylated groove 
between LRR12 and LRR20 likely contributes to dsRNA binding.    
 
 
 
C
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Two recent studies by Lee and colleagues greatly contributed to unravel the 
mode of TLR ligand binding. Using hybrid proteins consisting of portions of TLR-LRR 
and LRRs from variable lymphocyte receptor (VLR) found in hagfish, the crystal 
structure of both the TLR4/MD-2 and the TLR1/TLR2 complex respectively bound to 
eritoran, an antagonistic LPS analogue, and Pam3CSK4, a synthetic lipopeptide TLR2 
agonist, was resolved  (Kim et al., 2007; Jin et al., 2007). Surprisingly, the nature of 
ligand binding completely differs between both complexes. In contrast with the 
abovementioned predictions of TLR3-ligand binding and with the structure of the 
TLR1/TLR2/Pam3CSK4 complex, TLR4 associates with MD-2-eirtoran at its concave 
surface. Another striking feature of this structure is that no direct interaction between 
eritoran and TLR4 was observed. Much in contrast, a lipid-binding pocket in the 
convex side of TLR2 ectodomain was shown to directly associate with two of the acyl 
chains of Pam3CSK4 whereas a similar binding pocket in TLR1 accommodates the 
third chain. This feature provides a structural basis for the requirement of TLR2-TLR1 
heterodimer formation in the recognition of tri-acetylated lipopeptides.  These studies 
suggest a bivalent model of ligand recognition by TLRs; Protein ligands are likely to 
bind the concave surface of the TLR ectodomain, whereas non-protein ligands could 
associate with the convex side. Additional studies should provide us clearer insight in 
the exact nature of ligand binding and specificity of TLRs. 
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Toll-Like receptors share their intracellular domain with the IL-1 receptor 
superfamily (IL-1R, IL-1RAPL, IL-18R and IL-33R). The TIR domain of TLRs and 
downstream adapters encompasses approximately 150 aa. Alignment of different TIR 
sequences revealed three highly conserved boxes of which box2 and box3 are 
involved in signalling (Fig.3A).  TIR domain structures are available for TLR1, TLR2 
and IL-1RAPL (Xu et al., 2000; Khan et al., 2004). The structures contain a central 
five-stranded parallel β-sheet, surrounded by five helices on both sides (Fig.3B).  The 
BB loop, linking the second β-strand with the second α-helix, on the surface of the 
TIR domain, contains a proline critical for signalling and therefore is thought to be 
involved in homotypic TIR domain interactions. 
 
 
 
 
Fig.3: TIR domain sequence and structure (adapted from Xu et al., 2000).  (A) TIR 
domain sequence alignment. Three regions, box1, box2 and box3 are conserved 
throughout all TIR domains. (B) TIR domain is comprised of 5 parallel β-sheets enclosed 
by 5 α–helices. The BB loop harbours a conserved proline or arginine residue, critical for 
signal transduction. 
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III. Expression pattern and cellular localisation of the different TLRs 
 
 
 
 
Toll-Like receptors are expressed on a diverse spectrum of haematopoietic and 
non-haematopoietic cells. However, expression of the different TLRs is not equally 
distributed among these cell types: macrophages, neutrophils and dendritic cells 
express most of the TLRs, whereas only a subset of TLRs can be found on 
fibroblasts, epithelial and endothelial cells. Based on their subcellular expression 
pattern, TLRs can be split up in two groups: TLRs expressed on the cell surface 
(TLR1, TLR2, TLR4, TLR5, and TLR6), involved in recognition of bacterial and fungal 
structures and endosomal/lysosomal expressed TLRs (TLR3, TLR7, TLR8, TLR9), 
capable of sensing viral and bacterial nucleic acids. Endosomal targeting of TLR3 is 
achieved by a short linker sequence between its transmembrane and TIR domain 
(Nishiya et al., 2005). In contrast, intracellular localisation of TLR7 and TLR9 was 
only dependent on their transmembrane domains (Barton et al., 2006; Nishiya et al., 
2005). The lysosomal and endosomal environment facilitates degradation of viruses 
and bacteria, resulting in the release of nucleic acids which are sensed by these 
intracellular TLRs. An additional reason for endosomal expression of some TLRs was 
provided through the analysis of a chimeric TLR9 protein. TLR9 recognizes 
unmethylated CpG DNA and suppression of this motif in vertebrate DNA is thought to 
be the discriminating factor between self and non-self DNA (Hemmi et al., 2000; 
Krieg et al., 1995). However, the TLR9N4C chimera, composed of the TLR9 
ectodomain and the TLR4 transmembrane and intracellular domain, is still responsive 
to self DNA (Barton et al., 2006). Contrary to wild type TLR9, this TLR9C4N chimera 
is expressed at the cell surface. Thus, next to the nature of the recognized DNA, 
intracellular localisation of TLR9 is involved in the discrimination of self and non-self 
DNA. 
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IV. Ligand specificity of Toll-Like receptors 
 
. 
Toll-Like receptors recognize a diverse pattern of viral, fungal and bacterial 
motifs, commonly designated as PAMPs. However, TLRs also sense chemical 
components and even endogenous or self ligands are detected. The following 
section summarizes the diversity of TLR ligand recognition. 
 
TLR1/2/6 
 
 
LPS and peptidoglycan (PG), both bacterial cell wall components, were first 
identified as TLR2 ligands (Yang et al., 1998; Kirschning et al., 1998; Yoshimura et 
al., 1999), but more recent studies showed that purified LPS and PG do not provoke 
a TLR2-dependent response (Hirschfeld et al., 2000; Travassos et al., 2004). The 
originally observed effects of LPS and PG on TLR2 are caused by lipopeptide and 
lipoteichoic acid (LTA) contamination of the samples (Takeda et al., 2002; 
Schwandner et al., 1999). In response to certain ligands, TLR2 forms heterodimers 
with either TLR1 or TLR6. Analysis of TLR1-deficient macrophages revealed a role 
for TLR1/TLR2 heterodimers in response to bacterial triacetylated lipoproteins and 
the synthetic triacetylated lipopeptide Pam3CSK4 (Takeuchi et al., 2002). Moreover, 
TLR1/TLR2 heterodimers are also involved in the recognition of the outer-surface 
lipoprotein of  Borrelia burgdorferi and some soluble factors secreted by Neisseria 
meningitis (Alexopoulou et al., 2002; Wyllie et al., 2000). TLR2/TLR6 dimers on the 
other hand detect diacetylated lipopeptides since both TLR2-/- and TLR6-/- mouse 
embryonic fibroblasts (MEFs) failed to detect the diacetylated mycoplasmal 
macrophage-activating lipopeptide-2kDa (MALP-2) (Takeuchi et al., 2001; Takeuchi 
et al., 2002).     
Additionally, TLR2 recognizes protozoal glycosylphosphatidylinositol (GPI) 
anchors (Bafica et al., 2006; Campos et al., 2001), fungal phospholipomannan and 
zymosan (Underhill et al., 1999b; Kataoka et al., 2002; Jouault et al., 2003), Atypical 
LPS from Leptospira interrogans and Porphyromonas gingivalis (Hirschfeld et al., 
2001; Werts et al., 2001), Modulin, a factor secreted by Staphylococcus epidermidis 
(Hajjar et al., 2001), Neisserial porins (Massari et al., 2002), hemagglutinin protein of 
wild-type measles virus (Bieback et al., 2002) and envelope proteins from Human 
Cytomegalovirus (HCMV) (Compton et al., 2003). 
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TLR Cellular compartment Exogenous Ligands Ligand origin Reference 
     
TLR1* Cell surface Triacyl lipopeptides Bacteria/Mycobacteria (Takeuchi et al., 2002) 
  Soluble factors Neisseria meningitis (Wyllie et al., 2000) 
  Outer-surface lipoprotein OspA Borrelia burgdorferi (Alexopoulou et al., 2002) 
TLR2 Cell surface Peptidoglycan Gram-positive bacteria (Yoshimura et al., 1999; Schwandner et al., 1999) 
  Lipotecichoic acid and related glycolipids Gram-positive bacteria 
(Schwandner et al., 1999; 
Opitz et al., 2001) 
  Phospholipomannan Fungi (Jouault et al., 2003) 
  Lipoarabinomannan Mycobacteria (Underhill et al., 1999a) 
  Atypical LPS Porphyromonas gingivalis (Hirschfeld et al., 2001) 
  Atypical LPS Leptospira interrogans (Werts et al., 2001) 
  Phenol-soluble modulin Staphylococcus epidermidis (Hajjar et al., 2001) 
  Lipopeptides Bacteria (Takeda et al., 2002) 
  GPI anchor Protozoa (Campos et al., 2001; Bafica et al., 2006) 
  Envelope protein Virus (Compton et al., 2003) 
  Hemagglutinin Virus (Bieback et al., 2002) 
  Porins Bacteria (Massari et al., 2002) 
  Zymosan Fungi (Underhill et al., 1999b) 
TLR3 Endosomal/ Cell surface** dsRNA Virus 
(Alexopoulou et al., 2001; 
Wang et al., 2004) 
TLR4 Cell surface Lipopolysaccharide Gram-negative bacteria (Poltorak et al., 1998) 
  HSP60 Chlamydia pneumoniae (Bulut et al., 2002) 
  Flavolipin Flavobacterium meningosepticum (Gomi et al., 2002) 
  Mannan Fungi (Tada et al., 2002) 
  Glycoinositolphospholipids Protozoa (Oliveira et al., 2004) 
  Taxol Plant (Perera et al., 2001) 
  Envelope protein Virus (Rassa et al., 2002) 
  RSV fusion protein Virus (Kurt-Jones et al., 2000) 
   
 
TLR5 Cell surface Flagellin Bacteria (Hayashi et al., 2001) 
TLR6* Cell surface Diacyl lipopeptides Bacteria/Mycobacteria (Takeuchi et al., 2001) 
TLR7/ 
TLR8 Endosomal Imidazoquinoline-like molecules Synthetic molecule (Hemmi et al., 2002) 
  ssRNA Virus (Heil et al., 2004) 
  Guanosine analogs Synthetic molecule (Lee et al., 2003) 
TLR9 Endosomal CpG DNA Bacteria/Protozoa/Virus (Hemmi et al., 2000) 
  Hemozoin Protozoa (Coban et al., 2005) 
TLR11 Cell surface Components of uropathogenic bacteria Bacteria (Zhang et al., 2004) 
  Profilin like molecule Protozoa (Yarovinsky et al., 2005) 
Table 1: Recognition of pathogen-associated molecular patterns by mammalian TLRs. 
*  Ligand recognition by TLR1 and TLR6 requires heteromeric dimers with TLR2. 
**  TLR3 is mostly expressed in endosomal compartments, but can also be found on the cell 
surface of human fibroblasts (Matsumoto et al., 2003). 
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TLR3 
 
 Double-stranded RNA (dsRNA) is produced during the course of some viral 
infections and is the natural ligand of TLR3.  Overexpression of TLR3 in Hek293 cells 
resulted in responsiveness to synthetic dsRNA (poly(I:C)) and TLR3-deficient mice 
were less susceptible to these ligands (Alexopoulou et al., 2001). Recent findings 
suggest that TLR3, in addition to dsRNA, also recognizes single strand polyinosinic 
acid (Marshall-Clarke et al., 2007). 
 Gene-targeting studies questioned the importance of TLR3 as a dsRNA 
sensor. Absence of TLR3 did neither alter the viral pathogenesis nor the production 
of type I IFNs following lymphocyticchoriomeningitis virus (LCMV), vesicular 
stomatitis virus (VSV), murine cytomegalovirus (MCMV), reovirus, Sendai Virus 
(SeV) and Newcastle disease virus (NDV) infection in fibroblasts and conventional 
DCs (Edelmann et al., 2004; Honda et al., 2003; Lopez et al., 2004), although some 
data could not be confirmed by others (Hoebe et al., 2003). Moreover, several other 
viral RNA sensors, like the RIG-I-Like receptor family, have been described over the 
past years (see later), further questioning the precise role of TLR3 in viral defence.   
 
TLR4 
 
TLR4 was the first human homologue to Drosophila Toll to be described 
(Medzhitov et al., 1997). Identification of a PÆ H mutation in the TLR4 gene of the 
LPS-hyporesponsive mouse strain C3H/HeJ together with the observation that TLR4-
deficient macrophages did not respond to LPS stimulation, established LPS as a 
natural ligand for TLR4 (Poltorak et al., 1998; Hoshino et al., 1999). LPS is a major 
glycolipid component of the outer cell wall of Gram-negative bacteria with strong 
immunostimulatory capacities, emphasized by its role in endotoxic shock.  
Susceptibility of the mouse strain C3H/HeJ to Salmonella typhimurium, Escherichia 
coli and Neisseria meningitis infection underscores the importance of TLR4 in vivo 
(Woods et al., 1988; Hagberg et al., 1985; O'Brien et al., 1982). 
TLR4 requires co-receptors, like CD14, MD-2 and the LPS-binding protein 
(LBP), to provoke a potent LPS-response (Jerala, 2007). First, the serum protein LBP 
binds LPS, resulting in disruption of LPS aggregation. Next, LBP delivers monomeric 
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LPS to CD14, which in turn transfers LPS to MD-2. Finally, the MD-2:LPS complex 
associates with the ectodomain of TLR4, which triggers intracellular signal 
transduction.  
Next to LPS, other bacterial components are recognized by TLR4 such as 
Heat shock protein 60 (HSP60) of Chlamydia pneumoniae (Bulut et al., 2002) and 
flavolipin, an amino acid-containing lipid unique to  Flavobacterium meningosepticum 
(Gomi et al., 2002). 
TLR4 is also involved in fungal, protozoal and viral defence, as it respectively 
responds to mannans from Saccharomyces cerevisiae and Candida albicans (Tada 
et al., 2002), glycoinositolphospholipids from Trypanosoma cruzi (Oliveira et al., 
2004) and the fusion protein from Respiratory Syncytial Virus (RSV) (Tada et al., 
2002; Oliveira et al., 2004; Kurt-Jones et al., 2000).  In addition, it was shown that 
TLR4 interacts with Taxol, an antimitotic drug used in cancer therapy (Perera et al., 
2001)  
TLR5 
 
 TLR5 is mostly expressed on epithelial cells, monocytes and immature cells 
and is capable of sensing flagellin, an essential protein of the bacterial flagella 
(Hayashi et al., 2001). It seems that only monomeric flagellin is recognised, as the 
TLR5 recognition site is embedded in the intact filamentous flagellar structure (Smith 
et al., 2003). TLR5 is expressed exclusively on the basolateral surface of intestinal 
epithelia, where it detects flagellin of invading bacteria (Gewirtz et al., 2001). Knock-
out studies revealed that the contribution of TLR5 to antibacterial host response is 
highly redundant with other TLRs (Feuillet et al., 2006). Moreover, TLR5-independent 
recognition of cytosolic flagellin by members of the NOD family is also observed 
(Franchi et al., 2006; Miao et al., 2006) and will be discussed later.  
 Surprisingly, TLR5-/- mice are more susceptible to infection of the urinary tract 
induced by Escherichia coli, a feature shared with the highly related TLR11 (see 
below). No functional TLR11 is expressed in humans, suggesting that human TLR5 is 
the predominant receptor for uropathogenic E.coli detection (Andersen-Nissen et al., 
2007) .  
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TLR7/8 
 
 For a long time, the natural ligand for murine TLR7 and human TLR8 
remained unidentified. However, it was known that small antiviral components, like 
imiquimod (R-837), resiquimod (R-848) and loxoribine can elicit a strong TLR7/8 
response (Hemmi et al., 2002; Jurk et al., 2002). Together with the endosomal 
expression pattern analogous to TLR3, these observations suggested a role for 
TLR7/8 in antiviral defence. As these antiviral components are structurally related to 
nucleic acids, it came as no surprise that TLR7 and TLR8 recognize guanosine- and 
uridine-rich single stranded RNA from HIV-1 (Heil et al., 2004). Moreover, DCs and 
B-cells derived from TLR7-/- mice display a reduced response against ssRNA viruses 
like influenza and VSV (Lund et al., 2004; Diebold et al., 2004). Recently it was 
shown that nucleoside modification and the origin of RNA has a drastic effect on RNA 
recognition by TLR3/7/8 (Kariko et al., 2005). In this report, the authors show that 
modified nucleosides, like N6-methyldenosine, pseudouridine, 5-methylcytidine, 2-
thiouridine and  5-methyluridine generally suppresses TLR-induced responses and 
that this suppression is proportionally to the number of modified nucleosides. This 
observation suggests that RNA modification rather than endosomal expression of 
TLRs is the mechanism to discriminate between host and pathogen RNA since much 
more nucleoside modifications are observed in mammalian RNA compared to viral 
and bacterial DNA. The observed immunogenic effects of host RNA could be 
attributed to the poorly-modified mitochondrial RNA. Of note, nucleoside modification 
(i.e. N6-methyldenosine) is observed in various viruses, like RSV, HSV and SV40, 
and this modification could allow viruses to evade TLR-mediated immune responses. 
These findings have implications on the therapeutic applications of synthetic RNA. 
Avoiding nucleotide modifications results in an increased immunogenicity and 
therefore could improve RNA-based vaccines or the application of RNA as adjuvant. 
Conversely, introducing RNA modifications may enhance RNAi efficiency.   
  
 
 
 
 
 
 
 
 
 - 40 -
TLR9 
 
 Unmethylated bacterial CpG DNA is recognized by TLR9, as was shown by 
the study of TLR9-deficient mice who failed to produce inflammatory cytokines in 
response to CpG challenge (Hemmi et al., 2000). In analogy with RNA recognition by 
TLR3/7/8, discrimination between self and non-self DNA is based on the nature of the 
recognized ligand and the endosomal expression of TLR9. CpG motifs in mammalian 
DNA are very rare and readily methylated and host DNA does not frequently enter 
the endosomal compartments (Barton et al., 2006). Another source of CpG motifs are 
viruses, and these sequences are also recognized by TLR9 (Krug et al., 2004; Lund 
et al., 2003). Although  haemozoin, a hydrophilic heme polymer produced by malaria 
parasites, was reported as a non-DNA ligand of TLR9 (Coban et al., 2005), recent 
data revealed that DNA contamination of haemozoin could be the real activator 
(Parroche et al., 2007). In addition, TLR9-independent mechanisms have evolved to 
detect foreign DNA intracellularly, and these will be discussed later.    
 
TLR11 
  
 In contrast to its human analogue which contains a stop codon, mouse TLR11 
is fully functional. Recently, mouse TLR11 was shown to detect uropathogenic 
bacteria (Zhang et al., 2004) and profilin-like molecules from Toxoplasma gondii 
(Yarovinsky et al., 2005).  
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TLR responses to self ligands. 
 
Next to pathogen-derived ligands, TLRs recognize some endogenous 
products, such as heat shock proteins (HSPs) and extracellular matrix proteins 
(Table 2). These self ligands are mostly released after tissue damage or inflammation 
and are called therefore danger-associated molecular patterns or DAMPs.  
HSPs, chaperone proteins involved in protein folding and trafficking, form a 
substantial subset of self ligands. The mitochondrial HSPs, HSP60 and HSP70 
respectively induce TNF-α/NO and IL-12 production in macrophages in a TLR2- 
(HSP60) or TLR2/TLR4(HSP70)-dependent manner (Ohashi et al., 2000; Vabulas et 
al., 2001; Vabulas et al., 2002b; Asea et al., 2002). Moreover, an endoplasmic 
reticulum HSP, gp96, was shown to induce pro-inflammatory cytokines production 
and upregulation of co-stimulatory molecules in bone-marrow derived DCs. This 
immunostimulatory effect was shown to be dependent on TLR2 and TLR4 signalling 
since DCs derived from TLR4 mutant and TLR2/TLR4 double mutant mice lost 
responsiveness to gp96 (Vabulas et al., 2002a). Of note, this gp96 recently was 
identified as the key chaperone involved in cell surface and intracellular expression of 
TLRs (Yang et al., 2007). Moreover, the small HSPs αA crystalline and HSPB8 were 
identified as a TLR4 ligands (Roelofs et al., 2006). Synovial tissue from patients with 
rheumatoid arthritis abundantly expresses the small nuclear HSPB8 or HSP22 
protein which activates DCs through interaction with TLR4 (Roelofs et al., 2006). 
These data point to a possible role for HSPB8 in the inflammatory state of 
rheumatoid arthritis. 
 Cleavage of extracellular matrix (ECM) proteins is a common phenomenon 
observed in tissue injury. Some of these degradation products are detected by TLRs, 
leading to the activation of DCs and macrophages. These ligands include hyaluronan 
(TLR2/TLR4), heparan sulphate (TLR4), fibrinogen (TLR4), fibronectin (TLR4), 
biglycan (TLR2/TLR4) and surfactant protein-A (TLR4) (Termeer et al., 2002; 
Johnson et al., 2002; Smiley et al., 2001; Okamura et al., 2001; Schaefer et al., 2005; 
Guillot et al., 2002). These findings suggest a role for Toll-Like receptors as “tissue- 
state sensors”. 
  
 
 
 - 42 -
   
Endogenous TLR Ligand TLR Reference 
   
   
Heat Shock Proteins   
HSP60 TLR4 (Ohashi et al., 2000; Vabulas et al., 2001) 
HSP70 TLR2/TLR4 (Asea et al., 2002) 
gp96 TLR2/TLR4 (Vabulas et al., 2002a) 
αA Crystallin TLR4 (Roelofs et al., 2006) 
HSPB8/HSP22 TLR4 (Roelofs et al., 2006) 
   
   
Extracellular matrix  
proteins   
   
Hyaluronan TLR4 (Termeer et al., 2002) 
Heparan sulphate TLR4 (Johnson et al., 2002) 
Fibrinogen TLR4 (Smiley et al., 2001) 
Fibronectin extradomain A TLR4 (Okamura et al., 2001) 
Biglycan TLR2/TLR4 (Schaefer et al., 2005) 
Surfactant protein-A TLR4 (Guillot et al., 2002) 
   
   
Others   
   
β-defensin TLR4 (Biragyn et al., 2002) 
Minimally modified LDL TLR4 (Miller et al., 2003) 
HMGB1 TLR2/TLR4 (Park et al., 2004) 
DNA containing immune 
complexes TLR9 
(Tian et al., 2007) 
   
Table 2: Endogenous TLR ligands 
 
Next to HSPs and ECM proteins, other endogenous TLR ligands were 
described. Beta-defensins, epithelial antibacterial peptides produced upon mucosal 
infection, activate DCs in a TLR4-dependent way, thereby inducing upregulation of 
co-stimulatory molecules and cell maturation (Biragyn et al., 2002).   High-mobility 
group box 1 (HMGB1) protein, a chromatin-binding protein, was also identified as 
endogenous TLR2/TLR4 ligand (Park et al., 2004). HMGB1 is released in the 
extracellular medium either in a passive (released by necrotic cells) or an active 
manner (secreted by a variety of both immune and non-immune cells following 
inflammatory cytokine stimulation). Next to binding TLR2/TLR4, HMGB1 was also 
shown to interact with the receptor for advanced glycation end products (RAGE) (Hori 
et al., 1995). Recognition of HMGB1 by TLR2/TLR4 leads to the production of pro-
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inflammatory cytokine and DCs maturation (Park et al., 2004; Dumitriu et al., 2005). 
This DC maturation following HMGB1 stimulation was recently shown to be crucial for 
the outcome of anticancer therapy (Apetoh et al., 2007). In this report it was shown 
that the release of the high mobility group box 1 protein (HMGB1) by dying tumor 
cells is essential for instructing DCs to process and present tumor antigens. This DCs 
maturation was dependent on TLR4, since breast cancer patients carrying a loss-of-
function TLR4 polymorphism (see below) display a faster relapse after anti-tumor 
therapy than patients with the normal allele. It remains unclear whether HMGB1 
directly induces its pro-inflammatory effects since studies using highly purified protein 
revealed that HMGB1 itself has little immunostimulatory properties (Rouhiainen et al., 
2007). Interaction of HMGB1 with nucleic acids or LPS was shown to drastically 
improve the pro-inflammatory activity of HMGB1 and therefore it was proposed that 
these complexes account for the immunostimulatory effects (Rouhiainen et al., 2007). 
In line with these findings, Tian and colleagues describe a role for HMGB1 in 
mediating TLR9 activation in response to DNA-containing immune complexes (Tian 
et al., 2007).  
In addition, minimally modified low density lipoprotein (mmLDL) was shown to 
induce actin polymerisation and macrophage spreading in a TLR2/TLR4-dependent 
manner (Miller et al., 2003). This endogenous TLR ligand is thought to be essential in 
the progression of atherosclerosis (see below). 
Taken together, these findings provide conclusive evidence for a broader 
function of TLRs, not only detecting pathogen invasion but also controlling tissue 
state.  
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V. TLR signalling. 
 
 
1. Early steps in TLR signalling 
 
 
Following ligand binding, Toll-Like receptor signalling is intiated by the 
recruitment of adaptor molecules through homotypic TIR-TIR domain interactions. At 
present four adaptor molecules are described: MyD88, Mal, Trif and Tram. Different 
TLRs can recruit different TLRs (Table 3) which, in part, explains TLR-specific 
responses. The following section overviews the structural and fuctionnal 
characteristics of these adaptor molecules. 
 
 
 
 
   
 TLR adaptor Recruited by References 
   
   
MyD88 All TLRs (TLR1-TLR11) except TLR3 
(Hacker et al., 2000; Hemmi et al., 2002; Kawai et al., 1999) 
   
   
Mal/TIRAP TLR2/TLR4 (Horng et al., 2002; Yamamoto et al., 2002a) 
   
   
Trif/Ticam-1 TLR3/TLR4 (Yamamoto et al., 2003a) 
   
   
Tram/Ticam-2 TLR4 (Yamamoto et al., 2003b) 
   
Table 3: Adaptor usage by different mammalian Toll-Like receptors. 
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MAPPIT analysis of early Toll-Like receptor signalling events. 
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Abstract 
  
Toll-Like receptor (TLR) signalling is initiated by the recruitment of one or 
more adaptor proteins to the activated receptor complex. At present, four of these 
proteins are identified, namely MyD88, Mal, Trif and Tram and their selective usage 
by different TLRs in part accounts for TLR-specific transcriptional responses. Recent 
findings described unique biochemical properties for each of these TIR-domain 
containing adaptors and revealed that these adapters are subjected to post-
translational modification. We used MAPPIT (Mammalian Protein-Protein interaction 
Trap), a two-hybrid technique that functions in a mammalian cell context, to study 
the molecular interactions downstream of TLR activation. We demonstrate pathway 
walking from TLR4 to IRAK-1 and identified Mal as a bridging adaptor, linking MyD88 
to the activated TLR4.  
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Introduction  
  
The innate immune system provides first-line protection against the 
continuous threat of invading pathogens. The Toll-Like receptor (TLR) family, a 
group of germ-line encoded, type I transmembrane proteins, plays a key role in this 
immediate defence mechanism. TLRs sense a diverse pattern of pathogen structures 
like LPS (TLR4), dsRNA (TLR3), flagellin (TLR5) and bacterial lipoproteins (TLR2). 
TLR triggering leads to the production of pro-inflammatory cytokines including TNF-
α, IL-12 and type I interferons (IFNs) and primes the adaptive immune system. The 
signalling cascade originating from these TLRs is based on an intracellular Toll/ 
Interleukin-1 Receptor (TIR) domain. TLRs use a limited set of four TIR-domain 
containing adaptors to convert an extracellular signal into an intracellular response, 
which in part accounts for ligand-specific responses. These four adaptors are myeloid 
differentiation primary response gene 88 (MyD88), MyD88-adaptor-like (Mal, also 
referred to as TIR-domain–containing adapter protein (TIRAP)), TIR-domain-
containing adaptor inducing interferon (Trif, also known as TIR-containing adaptor 
molecule (Ticam-1)) and Trif-related adapter molecule (Tram, or also called TIR-
containing adapter molecule-2 (Ticam-2) or TIR-domain containing adaptor (Tirp)). 
We here review the characteristics and functions of these adaptor proteins in TLR-
proximal signalling events. Moreover, applications of the mammalian protein-protein 
interaction trap (MAPPIT) two-hybrid system for studying these signalling cascades 
will be discussed.  
 
 
 
MyD88 
 
 MyD88 was the first TLR adaptor to be described. It was identified originally 
as a gene activated in M1D+ myeloid precursors following IL-6-induced terminal 
differentiation and growth arrest [1]. Only several years later, its central function in 
IL-1R[2-5] and TLR[6] signalling became apparent. Consequently, MyD88-deficient 
mice exhibit impaired responses to IL-1 and agonists of all TLRs except TLR3 [7-12].  
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MyD88 is composed of a C-terminal TIR domain and an N-terminal Death 
Domain (DD) linked together by a short intermediate domain (Fig.1). Signalling is 
initiated by interaction of MyD88 and the intracellular domain of an activated TLR 
through TIR-TIR association and this event results in the recruitment of the 
downstream serine/threonine IL-1 receptor-associated kinase-4 (IRAK-4) to MyD88 
via a homotypic Death Domain association [13;14]. The intermediate domain is also 
crucial since an alternative splice variant of MyD88 lacking this region, MyD88s, failed 
to recruit IRAK-4 and therefore acts as a negative regulator of TLR signalling [15]. 
Next, IRAK-4 interacts with IRAK-1, resulting in the phosphorylation and activation of 
the latter. Activated IRAK-1 autophosphorylates itself, leading to its dissociation of 
the MyD88/IRAK-4 complex and the association with TNF receptor-associated factor-
6 (TRAF-6). Activation of TRAF6 ultimately leads to the activation of NF-κB and 
MAPKs through a series of phosphorylation and ubiquitination steps (Fig.2, reviewed 
in [16]).  
 In addition to IRAK recruitment, MyD88 was also shown to associate with 
members of the interferon regulatory factor (IRF) family. Two-hybrid screenings 
identified IRF7 as a MyD88 interacting protein, and this interaction is essential in 
TLR9-induced type I IFN production [17;18]. Moreover, MyD88 interacts with IRF5 
and IRF1, leading to the activation of pro-inflammatory cytokines [19;20]. The 
specific function and regulation of  IRFs  in TLR signalling is reviewed elsewhere 
[21]. 
 
Mal 
 
 LPS stimulation of MyD88-/- cells still results in a significantly delayed NF-κB 
activation. Furthermore, IRF3 activation and concomitant IFN-inducible gene 
induction is unaffected [8;22]. These findings suggested the existence of a “MyD88-
independent” pathway. Therefore the human genome was screened for TIR 
containing molecules that could fill this gap in the TLR4 signalling cascade. The first 
adaptor to be identified was Mal [23;24]. Overexpression studies using a dominant 
negative variant of Mal revealed a function for Mal in TLR2 and TLR4, but not in 
TLR9 or IL-1R signalling [23;24]. Analysis of Mal-/- mice confirmed this restricted role 
 - 48 -
for Mal, as early-phase NF-κB activation, and concomitant TNF-α, IL-6 and IL12p40 
production was severely impaired following TLR2 and TLR4 stimulation [25;26]. 
However, LPS-induced late-phase NF-κB induction and IRF3 phosphorylation 
remained intact. Thus, Mal is not the adaptor involved in MyD88-independent 
signalling but acts as a bridging adaptor linking MyD88 to the activated TLR2 or 
TLR4. 
 In line with these observations, Mal was shown to possess a 
phosphatidylinositol 4,5-bisphosphate (PIP2) binding domain in its N-terminus [27]. 
This domain mediates Mal recruitment to PIP2-rich areas in the plasma membrane 
and was shown to be essential in facilitating MyD88 delivery to an activated TLR4.  
 
 
 
 
 
Figure 1: Overview of interaction domains of TIR-containing adaptor molecules. All TLR 
adaptors contain a Toll-IL-1R (TIR) interaction domain. In addition, MyD88 consists of a small 
intermediate domain and an N-terminal Death Domain (DD), by which it recruits downstream kinases. 
Mal is phosphorylated by Bruton’s tyrosine kinase on tyrosine 86 and 187. An N-terminal PIP2-binding 
motif ensures recruitment of Mal to the plasma membrane. A TRAF6-binding motif in its TIR domain 
accounts for Mal-induced NF-κB activation. Mal is cleaved by caspase-1 at position 198. The N-
terminus of Trif contains several TRAF6-binding regions, of which motif 248-255 is thought to be 
essential in TRAF6 recruitment. Moreover, Trif contains a C-terminal RIP homotypic interaction motif 
(RHIM). The N-terminus of Tram is myristoylated, which in analogy with Mal, directs Tram to the cell 
membrane and PKCε phosphorylates serine residues 6 and 16.   
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In addition, other biochemical properties of Mal were described over the past 
years. Upon TLR2 and TLR4 stimulation, Mal is phosphorylated by Bruton’s tyrosine 
kinase (Btk). Phosphorylation of Y86, and Y187 was shown to be crucial for LPS-
induced NF-κB activation[28]. In addition, Btk phosphorylates the p65 subunit of NF-
κB, which results in transactivation of gene expression [29]. Phosphorylated Mal is a 
target for proteasomal degradation, mediated by SOCS-1. Thus, Mal phosphorylation 
is an essential step in TLR2/TLR4 signalling, not only crucial for activation of the NF-
κB pathway, but also preventing a prolonged and possible harmful TLR signal.        
Mal also comprises a TRAF6-binding motif in its TIR domain and Mal was 
shown to coimmunoprecipitate with TRAF6 [30]. Abrogation of this TRAF6-
recruitment site leads to the loss of NF-κB activation upon TLR2- or TLR4-
stimulation, suggesting that Mal links TRAF6 to TLR2 and TLR4. However, this 
putative regulatory role for Mal in NF-κB induction contrasts with the observation 
that Mal overexpression in MyD88-/- did not lead to NF-κB activation, whereas 
overexpression of MyD88 in Mal-/- cells did result in induction of NF-κB [31]. 
Interaction of PKCδ and the TIR domain of Mal was also demonstrated [32]. 
siRNA-mediated depletion op PKCδ in RAW264.7 cells abolished TLR2- and TLR4-
mediated phosphorylation of p38 MAPK, IKK, and IκB, implying a essential role for 
PKCδ in Mal signalling.  
Additionally, yeast two-hybrid experiments revealed the interaction between 
Mal and Caspase-1 [33]. Moreover, Mal was shown to be cleaved by caspase-1 after 
position D198 and this process is required for downstream signalling.  
Mal is the most polymorphic TLR adaptor and various Mal polymorphisms, in 
contrast to polymorphisms of other TLR adaptors, can be linked to an altered 
susceptibility for various diseases.  A study by Hawn et al. described 4 Mal 
polymorphisms present in Vietnamese tuberculosis patients [34]. One synonymous 
mutation (C558T; Ala186Ala) was associated with increased susceptibility for 
tuberculosis and TLR2, but not TLR4 agonist stimulation of lymphocytes of patients 
homozygous for this mutation, resulted in a decrease in IL-6 production. It remains 
unclear how this variant, of which the aa sequence is not altered, can exhibit a 
different phenotype and linkage with other functional mutations therefore cannot be 
excluded. A study performed by Khor and colleagues described a S180L Mal variant, 
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of which heterozygous carriage is associated with protection against tuberculosis, 
bacteremia, malaria and pneumococcal disease [35]. Biochemical analysis revealed 
that MalS180L still interacts with MyD88 and Mal, but is not capable of TLR2 binding. 
Since homozygous MalS180L individuals are rarely found, and homozygosity is 
associated with increased susceptibility for invasive pneumococcal disease, Khor et 
al. hypothesized that MalS180L heterozygosity results in an optimal intermediate 
immune response. 
 
 
Trif 
 
 The observation that Mal-deficiency did not lead to the abrogation of IRF3 and 
late phase NF-κB activation upon LPS stimulation, suggested the existence of other 
TLR adaptor proteins. Further database screenings were preformed and this resulted 
in the identification of Trif [36]. Overexpression of Trif leads to the activation of NF-
κB, although at a lower extent compared to Mal and MyD88. However, Trif activates 
the IFNβ-promoter at much higher level then MyD88 and Mal. Trif was also shown to 
coimmunoprecipitate with IRF3 and TLR3, and a dominant negative variant of Trif 
inhibited TLR3-mediated IRF3 activation. Concurrently, a yeast two-hybrid study 
identified Trif as a TLR3 interacting protein, and likewise characterized it as a 
mediator of TLR3-induced IRF3 activation [37]. In line with these findings, a 
chemically induced mutation in the Trif gene was described and this Lps2 mutation 
abolished TLR3- and TLR4-mediated responses [38].  
 Analysis of Trif-/- cells established Trif as an adaptor involved in the MyD88-
independent pathway, since IRF3 activation upon TLR3- or TLR4-stimulation was 
completely lost in these cells[12]. Trif-deficiency resulted also in a severely impaired 
NF-κB activation in response to TLR3 agonist stimulation, pointing at an essential and 
unique role for Trif in TLR3-mediated IRF3 and NF-κB induction. Activation of NF-κB 
upon LPS stimulation on the other hand was not affected in Trif-deficient cells. Mice 
deficient in both MyD88 and TRIF showed complete loss of NF-κB activation following 
TLR4 triggering, suggesting that Trif accounts for the MyD88-independent late phase 
NF-KB activation.  
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  Distinct regions of Trif are involved in NF-κB and IRF3 activation. The N-
terminal part of Trif is involved in IRF3 activation by complex formation with NF-κB-
activating kinase-associated protein 1 (NAP1) [39], TRAF family member-associated 
NF-κB activator (TANK)-binding kinase (TBK1) [40], TRAF3 [41] and TANK [42], of 
which TBK1 is the crucial kinase for IRF3 activation (Fig.1).  
In analogy with Mal, several putative TRAF6 binding sites were found in the N-
terminal part of Trif [40;43]. Mutation of the motif at position 248-255, reduced NF-
κB activation by Trif. However, the importance of TRAF6 in Trif-mediated NF-κB 
induction is somewhat unclear, as TLR3 signalling was not impaired in TRAF6-/- 
macrophages [44], in contrast with the drastic effect observed in TRAF6-/- mouse 
embryonic fibroblasts (MEFs) [43]. These findings indicate that the role of TRAF6 in 
NF-κB activation seems to be cell type-specific. 
 In addition to TRAF6 interaction, another mechanism of Trif-mediated NF-κB 
activation was described. Trif contains a receptor-interacting protein (RIP) homotypic 
interaction motif (RHIM) at its C-terminus by which it recruits RIP1 [45;46]. RIP1 
was shown to be critical in the Trif-NF-κB pathway since TLR3-induced activation of 
NF-κB, but not JNK or IRF3, was abolished in MEFs lacking RIP1 [45;46]. 
 Next to its role in NF-κB activation, RIP1 is also involved in Trif-induced 
apoptosis, through its association with FADD and caspase-8 [47]. 
 
 
Tram 
 
Database searches identified a fourth TIR-containing adapter, Tram. 
Concurrently, two groups revealed a function of Tram in TLR4 signalling [48;49]. 
Based on two-hybrid and coimmunoprecipitation studies, Tram was shown to bind to 
TLR4 and Trif, but not to other TLRs or MyD88. Overexpression of Tram induces the 
activation of NF-κB and IRF3 and both overexpression of a dominant negative variant 
of Tram as well as siRNA knockdown of Tram, resulted in an impaired TLR4-induced 
NF-κB and IFN-β induction. TLR3 responses on the other hand remained unaffected 
upon Tram knockdown. In addition, overexpression of a dominant negative Trif 
mutant or Trif-knockdown completely suppressed Tram-induced activation of the 
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IFN-β promoter. These data suggested a role for Tram in TLR4 signalling upstream 
of Trif.   
The role of Tram in TLR4 signalling was further underscored by analysis of 
Tram-/- mice [50]. In contrast to the findings of Bin and colleagues [51], IL-1 
signalling was unaffected in Tram-/- MEFs. However, TLR4- but not TLR2-, TLR3-, 
TLR7- or TLR9-induced cytokine production was severely suppressed in knock-out 
macrophages. Taken together, these data suggest a limited function for Tram in TLR 
signalling, being the bridging adaptor linking Trif to the activated TLR4. 
Recently, two post-translational modifications of Tram were described, both 
capable of modulating Tram’s activity. Tram contains an N-terminal myristoylation 
site, which is essential for membrane targeting of Tram. Disruption of the 
myristoylation leads to impaired LPS signalling [52]. Tram is also phosphorylated on 
serine 6 and serine 16 by PKCε upon LPS stimulation [53]. Disruption of the 
modification site again results in abrogated signalling. Phosphorylation of Tram leads 
to the translocation from the nucleus, but the exact consequence of this process is 
still elusive. Given the fact that phosphorylation of Tram is indispensable for 
signalling, translocation of Tram could facilitate the interaction with downstream 
signalling molecules. 
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Figure 2: TLR4 signalling pathways. TLR signalling commonly is divided in a MyD88-dependent 
and Trif-dependent branch. MyD88-dependent signalling: TLR4 activation leads to the recruitment of 
adaptor molecules Mal and MyD88 to the receptor, through TIR-TIR domain interactions. Next, IRAK-4 
interacts with MyD88, leading to the association and phosphorylation of IRAK-1. Phosphorylated IRAK-
1 dissociates from the MyD88/IRAK-1 complex and binds TRAF6, which in turn activates TAK1 in an 
ubiquitin-dependent manner. Subsequently, TAK1 activates the IKK complex and the MAPK pathway, 
ultimately leading to the activation of respectively NF-κB and AP-1. Trif-dependent signalling: 
Triggering TLR4 leads to the recruitment of Tram and Trif to the activated receptor. Next, Trif recruits 
the IKKi/TBK1 complex, leading to the phosphorylation and nuclear translocation of IRF3. Moreover, 
Trif signalling leads to the activation of NF-κB and MAPKs, mediated by the association of Trif with 
RIP1 and TRAF6. 
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Applications of the MAPPIT Toolbox in TLR signalling 
 
Contrary to the growing insight in the function and regulation of the adaptor 
molecules in TLR signalling, reports biochemically linking these adaptors to the TLRs 
remain scarce. Moreover, the applied methods are generally limited to yeast two-
hybrid and coimmunoprecipitation [54]. These techniques suffer from some intrinsic 
limitations. As discussed above, the TLR adaptors are subjected to post-translational 
modifications, which are hard to reproduce in yeast. Coimmunoprecipitation on the 
other hand leads to disruption of the cell architecture, which can result in false 
positive interactions between proteins that normally localise in separate cellular 
compartments. 
  To circumvent these problems, we developed MAPPIT (MAmmalian 
Protein-Protein Interaction Trap), a mammalian two-hybrid method based on type I 
cytokine signalling [55]. Ligand-induced cytokine receptor clustering results in cross-
phosphorylation and activation of receptor-associated Janus kinases (JAKs) (Fig.3A). 
Thereupon, these activated JAKs phosphorylate conserved tyrosine residues in the 
cytokine receptor tails, thus forming recruitment sites for signal transducer and 
activator of transcription (STAT) molecules. The STAT molecules subsequently are 
phosphorylated by the JAKs and translocate as dimers to the nucleus where they 
induce specific gene transcription. 
The MAPPIT technique exploits this JAK/STAT signalling pathway. In brief, we 
made a C-terminal fusion of a given ‘bait’ protein with the transmembrane and 
intracellular part of a class I cytokine receptor that is deficient in STAT3 recruitment. 
The extracellular domain of both the erythropoietin and the leptin receptor can be 
used. The ‘prey’ protein on the other hand is linked to a series of 6 functional STAT3 
recruitment sites of the gp130 chain. Association of bait and prey and ligand 
stimulation leads to STAT3 activation and induction of a STAT3–responsive luciferase 
reporter (rPAPI-Luci). The stimulation of the reporter gene is used as a measure of 
the interaction between the bait and prey proteins (Fig.3B). An additional advantage 
of the MAPPIT technique is the separation of interaction (cytosol) and effector 
(nucleus) zone since signal readout is mediated by endogenous STAT molecules. 
That way bait and prey proteins cannot interfere with reporter transcription, thereby 
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reducing autoactivators and false positives. The standard MAPPIT assay makes use 
of the human embryonic 293T (HEK293T) cells, but it can be used in other cell types, 
as long as these cells sufficiently express STAT3. Cells expressing STAT5 can also be 
applied, through the use of the  βc-MAPPIT variant [56]. Examples of applications of 
the MAPPIT technique are given in references 57-60.  
 
 
 
 
 
 
Figure 3: (A) Schematic overview of the JAK-STAT signal transduction pathway: ligand-induced 
cytokine receptor clustering results in the cross-phosphorylation and activation of associated JAK 
kinases. Next, these activated JAK kinases phosphorylate conserved tyrosine motifs in the cytoplasmic 
tails of the cytokine receptor. These phosphorylated tyrosine motifs form docking sites for STAT 
molecules, which in turn get phosphorylated. Those activated STATs dissociate from the receptor and 
translocate as dimers to the nucleus, where they induce transcription of specific genes. (B) MAPPIT 
principle: a given ‘bait’ is C-terminally fused with the transmembrane and intracellular part of a leptin 
receptor that is deficient in STAT3 recruitment. The extracellular domain of either the erythropoietin 
(EpoR) or of the leptin receptor (LR) can be used.  The ‘prey’ protein is linked to a series of 6 
functional STAT3 recruitment sites of the gp130 chain. Association of bait and prey and ligand (L) 
stimulation leads to STAT3 activation and induction of a STAT3–responsive luciferase reporter (rPAPI-
Luci).   
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Using MAPPIT we were able to reconstruct the signalling steps from TLR4 to 
IRAK-1. Therefore, the intracellular part of TLR4, the TLR adaptors and downstream 
kinases were cloned as either bait or prey. TLR signalling is initiated by ligand-
induced receptor dimerisation, resulting in the recruitment of adaptor molecules. 
Using MAPPIT, the TLR4 homodimerisation could clearly be detected (Fig.4A). 
Moreover, recruitment of Tram or Mal could also be monitored (Fig.4B-C). Much in 
contrast, no association of TLR4 and MyD88 was detected, although the role of 
MyD88 in TLR4 signalling is well documented [8].  However, co-transfection of a Mal 
expression vector together with TLR4ic-bait and MyD88-prey resulted in a clear 
MAPPIT signal (Fig.4E). These data are consistent with the recent definition of Mal as 
a bridging adaptor, linking MyD88 to TLR4 [27] and prove that indirect interactions 
can be detected using the MAPPIT assay. In addition, heterodimerisation of Mal and 
MyD88 was readily observed (Fig.4D) and interaction of MyD88 and the downstream 
kinase IRAK-4 was also detected (Fig.4F).  Again, we could observe the indirect 
association of Mal and IRAK-4, with a bridging role for MyD88 (Fig.4G). Finally, using 
IRAK-4 as a bait interaction with the IRAK-1-prey was demonstrated (Fig.4H).  
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Figure 4: (A) Homodimerisation of TLR4.  Hek293T cells were transiently co-transfected with the 
MAPPIT TLR4ic-bait plasmid, the TLR4ic-prey or a SVT-prey as negative control, and the STAT3-
responsive rPAPI-luci reporter. Twenty-four hours after transfection the transfected cells were 
stimulated with leptin (100ng/ml) for another 24 h or were left untreated. Luciferase measurements 
were performed in triplicate. Data are expressed as mean fold induction (ratio stimulated/untreated). 
A similar experimental set-up was used in all following experiments. (B-C) Adaptor recruitment by 
TLR4ic. Using the TLR4ic-bait and either the Mal-prey (B) or the Tram-prey (C) recruitment of these 
adaptors to TLR4 was monitored. (D) Heterodimerisation of Mal and MyD88. Hek293T cells were 
transiently co-transfected with the Mal-bait and the myd88-prey vectors together with the rPAPI-luci 
reporter. (E) Mal links MyD88 to TLR4. The effect of Mal expression on MyD88 association was 
assayed by co-transfection of a Mal expression vector, together with the MyD88-prey and TLR4ic-bait. 
(F) MyD88 and IRAK-4 association. Interaction of MyD88 and IRAK-4 was assayed using the 
MyD88-bait and the IRAK4-prey vectors. (G) MyD88 bridges IRAK-4 to Mal. Co-transfection of a 
MyD88 expression vector mediates the association of IRAK-4 and Mal.  (H) Heterodimerisation of 
IRAK-1 and IRAK-4. Using IRAK-4 as a bait and IRAK-1 as a prey, heterodimerisation of both 
kinases was monitored. 
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As discussed above, MyD88 is a universal adaptor used by all TLRs except 
TLR3. In contrast to the numerous reports discussing the impaired TLR responses of 
MyD88-deficient mice, biochemical data linking MyD88 to these TLRs remains limited. 
Therefore, we evaluated the interactions between the TIR domains of additional 
TLRs (TLR2, TLR3, TLR5, TLR7 and TLR 9) and MyD88 or Mal using MAPPIT (Table 
1). Next to the previously described association with TLR4, interaction between Mal 
and TLR2 was also detected. These data are consistent with the observation that 
Mal-deficient mice exhibit severely impaired TLR2 and TLR4 responses. Clearly, 
neither of these TLRs directly interacts with MyD88, but moreover, we also failed to 
detect an interaction between MyD88 and all other TLRs examined. In analogy with 
our data, no direct interaction between TLR9 and MyD88 could be detected using 
yeast two-hybrid [54]. Of note, TLR7 and TLR9 are expressed on acidic endosomes 
whereas TLR2, TLR4 and TLR5 signal from the cell membrane. How MyD88 is 
recruited to those TLRs residing in distinct cellular compartments is still unclear. Our 
findings suggest that TLR5, TLR7 and TLR9, in analogy with TLR2 and TLR4, may 
also use accessory proteins, although we cannot rule out at present that these 
interactions cannot be detected using MAPPIT. However, such failure cannot be 
attributed to a defective prey or bait since the MyD88-prey is fully functional (see 
above) and functional interaction of all TLR baits with a JAK2-interacting prey can be 
detected, ruling out some intrinsic inhibition of the MAPPIT signal (data not shown). 
 
 
 
 
 
 
 
 
 
Table 1: MAPPIT analysis of MyD88 and Mal recruitment by different TLRs. The intracellular part of 
several TLRs were used as bait whereas MyD88 or Mal were used as prey. Experimental setup was as 
in Figure 4.Positive MAPPIT signals are depicted in bold.  
 
 
 TLR2ic TLR3ic TLR4ic TLR5ic TLR7ic TLR9ic 
MyD88 2,28 1,01 1,22 1,2 0,9 1,1 
Mal 8,71 4,01 26,69 1,5 1,9 2,7 
 
bait
prey
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Taken together, these data illustrate that MAPPIT is a valuable tool to study 
TLR signalling in a near-optimal physiological context in mammalian cells. MAPPIT 
can also be used to screen for new interactors [57]. To this end, a STAT-induced 
surface tag is used as a selectable marker. Cells stably expressing the bait chimera 
and this reporter vector can be infected with a prey cDNA-library. Upon ligand 
administration, cells expressing interacting preys are sorted and deposited in single 
wells allowing identification of the prey-encoding cDNAs. Efficiencies up to 40% of 
cell clones expressing interactor preys have been obtained (unpublished results).  
Uncontrolled activation of TLR signalling can be observed in autoimmune 
diseases, chronic inflammation and bacterial sepsis. Because of their specific role in 
TLR signalling, TLR adaptor molecules are considered as legitimate therapeutical 
targets. Based on the MAPPIT concept, a reverse two-hybrid system was developed 
(Reverse MAPPIT) [58] to screen for molecules that disrupt protein-protein 
interactions. Assays are currently being optimised to use this Reverse MAPPIT set-up 
to search for proteins or small molecules that interfere with TLR signalling.   
 
Conclusion 
 
 Initial TLR signalling events are based on the recruitment of a limited set of 
TIR-containing adaptor molecules. The differential use of these adaptors by different 
TLRs contributes to a ligand-specific response. These adaptor molecules are 
subjected to post-translational modifications and their function is strictly regulated. 
Underscoring the importance of controlling TLR activation is the observation that 
unrestrained TLR signalling can result in excessive inflammation, autoimmune 
disorders and septic shock. Given the fundamental role of the adaptor molecules in 
TLR signalling, they are justifiable targets for drug development. Possible strategies 
include interfering with the relevant TIR/TIR interactions or with the critical post-
translational modifications of the adaptors. MAPPIT, with its near optimal 
physiological context, might be a helpful tool for analysing the molecular principles 
underlying TLR signalling and also as a screening tool for compounds interfering in 
this pathway.  
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2. MyD88-dependent signalling 
 
 Activation of TLRs by their ligands ultimately leads to the activation of NF-κB 
and IRFs. The initial steps of these signalling pathways are mediated by four TIR-
domain containing adaptors: MyD88, Mal, Trif and Tram. Different TLRs make use of 
different adaptor combinations, which results in the activation of distinct signalling 
pathways. These signalling cascades can be divided in a MyD88-dependent and a 
Trif-dependent branch (Fig.5). Association of MyD88 and the intracellular domain of 
an activated TLR results in the recruitment of serine/threonine IL-1 receptor-
associated kinase-4 (IRAK-4) via a homotypic Death Domain interaction (Janssens 
and Beyaert, 2003; Suzuki et al., 2002). Next, IRAK-4 interacts with IRAK-1, resulting 
in the phosphorylation and activation of the latter. Activated IRAK-1 
autophosphorylates itself, leading to its dissociation of the MyD88/IRAK-4 complex 
and the association with TNF receptor-associated factor-6 (TRAF-6). TRAF-6, a 
RING domain protein with E3 ligase activity, interacts with other E3 ubiquitin ligase 
proteins like ubiquitin-conjugating enzyme 13 (Ubc13) and Ubc-like protein Uev1A, 
resulting in the lysine 63 polyubiquitination of TRAF-6 (Deng et al., 2000; Lamothe et 
al., 2007).  Ubiquitinated TRAF6 then forms a complex with transforming growth 
factor-β-activated kinase 1 (TAK1) and TAK1-binding protein 1, 2 and 3 (TAB1, TAB2 
and TAB3), resulting in the ubiquitination and activation of TAK1 (Kanayama et al., 
2004; Besse et al., 2007). TAK1 is the branching point resulting in the activation of 
two pathways (Wang et al., 2001; Sato et al., 2005). On the one hand, TAK1 
activates the IKK complex, composed of IKKα, IKKβ and IKKγ/NEMO, which results 
in the phosphorylation and subsequent degradation of IκB protein. Proteasomal 
degradation of IκB is followed by nuclear translocation of NF-κB, resulting in gene 
induction of pro-inflammatory cytokines including TNF-α, IL-6 and IL-12p40 (Hayden 
and Ghosh, 2004; Chen, 2005). On the other hand, TAK1 phosphorylates mitogen 
activated protein kinase (MAPK) kinase 6 (MKK6) and MKK7, resulting in the 
activation of p38 MAPK and c-Jun N-terminal kinase (JNK). These MAPKs 
subsequently phosphorylate activator protein-1 (AP-1), resulting in the nuclear 
translocation and concomitant gene induction (Wang et al., 2001; Hanafusa et al., 
1999). The role of TAK1 in TLR signalling was further underscored by analysis of 
TAK1-/- embryonic fibroblasts and B cells, which display reduced activation of NF-κB, 
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JNK and p38 upon TLR stimulation (Sato et al., 2005). Moreover, extracellular signal-
regulated protein kinase 1 (ERK1) and ERK2 activation was as well impaired in 
TAK1-/- cells, further broadening the TAK1-activated MAPKs (Sato et al., 2005).  
 Next to TAK1, other MAPKKK are involved in TLR4-induced JNK, ERK and 
p38 activation. MAPK-ERK kinase kinase (MEKK3)- deficient macrophages exhibit 
impaired activation of NF-κB, JNK and p38, but not of ERK, upon LPS treatment 
(Huang et al., 2004). Contrary, Tumor progression locus 2 (Tpl2) kinase-deficient 
macrophages failed to activate ERK in response to LPS , whereas normal JNK and 
p38 activation is observed (Dumitru et al., 2000). Finally, apoptosis signal-regulating 
kinase 1 (ASK1) was shown to be involved in LPS-induced p38 activation 
(Matsuzawa et al., 2005), further diversifying the TLR4-induced MAPK pathway. 
 
 
Fig.5: Toll-Like receptor signalling pathways. (A) MyD88-dependent signalling. TLR 
activation leads to the recruitment of adaptor molecules MyD88 or Mal/MyD88 to the 
receptor, through TIR-TIR domain interactions. Next, IRAK-4 interacts with MyD88, leading 
to the association and phosphorylation of IRAK-1. Phosphorylated IRAK-1 dissociates from 
the MyD88/IRAK-1 complex and binds TRAF6, which in turn activates TAK1 in an ubiquitin-
dependent manner. Subsequently, TAK1 activates the IKK complex and the MAPK pathway, 
ultimately leading to the activation of respectively NF-κB and AP-1. (B) Trif-dependent 
signalling. Triggering TLR3 and TLR4 leads to the recruitment of respectively Trif or 
Tram/Trif to the activated receptor. Next, Trif recruits the IKKi/TBK1 complex, leading to the 
phosphorylation and nuclear translocation of IRF3. Moreover, Trif signalling leads to the 
activation of NF-κB and MAPKs, mediated by the association of Trif with RIP1 and TRAF6.  
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3. Trif-dependent signalling 
 
 
 Triggering of TLR3 and TLR4 leads, next to MyD88-dependent signalling, to 
the activation of the Trif-dependent pathway.  Trif associates either directly (TLR3) or 
through the bridging adaptor Tram (TLR4) with the activated TLR, again via TIR-TIR 
domain interactions.  Next, two non-canonical IKKs, inducible IKK (IKKi/IKKε) and 
TRAF family member-associated NF-κB activator (TANK)-binding kinase (TBK1), 
together with TRAF3 are recruited to the N-terminal part of Trif (Fitzgerald et al., 
2003; Oganesyan et al., 2006; Sharma et al., 2003). This complex also involves 
TANK and NF-κB-activating kinase-associated protein 1 (NAP1) (Guo and Cheng, 
2007; Sasai et al., 2005). Subsequently, IKKi/TBK1 phosphorylate IRF3, leading to 
the nuclear translocation of the latter and corresponding induction of IFNβ 
transcription (Hemmi et al., 2004; Perry et al., 2004; McWhirter et al., 2004). Next to 
IRF3, IRF7 is also phosphorylated by the IKKi/TBK1 kinase complex, although, in 
contrast with IRF3, IRF7 is poorly expressed in unstimulated cells. Following TLR 
stimulation, IRF7 expression is upregulated, and therefore IRF7 is thought to account 
for a sustained type I IFN response, rather then having a role in the initial induction of 
IFNβ (Sato et al., 1998; Levy et al., 2002).  
 Activation of NF-κB and MAPK following LPS stimulation, although delayed, is 
still observed in MyD88-deficient cells. Moreover, triggering of TLR3, which only 
makes use of Trif as adaptor, also leads to pro-inflammatory cytokine production   
(Hoebe et al., 2003; Yamamoto et al., 2002b; Yamamoto et al., 2003a). Thus, next to 
production of type I IFNs, Trif-dependent signalling also leads to the activation of NF-
κB and MAPKs. This activation is mediated by receptor-interacting protein 1 (RIP1), 
which interacts with the Rip homotypic interacting protein (RHIM) motif in the C-
terminal part of Trif. Consequently, TLR3-induced activation of NF-κB, but not JNK 
nor IRF3, was abolished in MEFs lacking RIP1 (Meylan et al., 2004; Cusson-
Hermance et al., 2005). Moreover, Trif was shown to interact with TRAF6, mediated 
by three TRAF6-binding motifs in its N-terminal region (Sato et al., 2003). Disruption 
of the TRAF6-binding motifs in Trif lead to impaired NF-κB activation and 
overexpression of a dominant negative TRAF6 mutant results in the abrogation of 
poly(I:C)-induced NF-κB activation, suggesting a major role for TRAF6 in Trif-
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dependent NF-κB activation. Taken together, recruitment of RIP1 and TRAF6 by Trif 
results in the activation of TAK1 leading to NF-κB and MAPK activation.  
 However, this model is somewhat questioned. In contrast, Gohda and 
colleagues observed no impaired NF-κB activation in TRAF6-/- macrophages upon 
poly(I:C) stimulation (Gohda et al., 2004), indicating that the role of TRAF6 in NF-κB 
activation seems to be cell type-specific. Moreover, delayed activation of TLR4/Trif-
induced NF-κB was shown to be based on IRF3 activation rather then on the 
Trif/RIP1/TRAF6 pathway and requires de novo synthesis of TNFα (Covert et al., 
2005; Werner et al., 2005). Consistently, suppression of IRF3 expression leads to a 
reduced late-phase NF-κB activation, suggesting that Trif-activated IRF3 induces 
TNF-α expression. Next, TNF-α activates the TNF receptor via an autocrine loop, 
resulting in activation of IKKs and concomitant late-phase NF-κB activation. In 
contrast, TLR3-induced NF-κB activation still occurs in RIP+/- TNFR-/- fibroblasts, 
arguing against the existence of an autocrine NF-κB activation loop (Meylan et al., 
2004). Hence, further studies are necessary to elucidate the exact roles of RIP, 
TRAF6, TBK1, and IRF3 in Trif-mediated NF-κB activation. 
   
4. Interferon regulatory factors in TLR signalling 
 
  
 Next to IRF3/7, several other members of the IRF family (IRF1Æ IRF9) are 
involved in TLR signalling (Fig.6). IRF1, IRF3, IRF5, IRF7 and IRF8 activate 
transcription of type I IFNs and pro-inflammatory cytokines, whereas IRF4 has a role 
in negative feedback (see below). An additional role for IRF7 in TLR signalling arose 
by the identification of a novel IFN-inducing pathway in plasmacytoid DC (pDC). This 
subset of DCs produces high amounts of IFNα following viral infection, and therefore 
is also known as type I IFN-producing cells (Colonna et al., 2004). Surprisingly, these 
cells do not express TLR3 nor TLR4, but instead produce high levels of TLR7 and 
TLR9. Moreover, IFNβ expression upon TLR9 stimulation was completely abrogated 
in MyD88-/- DCs. These findings suggested the involvement of the MyD88-dependent 
pathway instead of Trif-dependent signalling in CpG-induced IFNβ production 
(Hoshino et al., 2002; Hemmi et al., 2003). Two-hybrid screening identified IRF7 as a 
MyD88-interacting protein, and the MyD88-IRF7 complex also involves IRAK-1, 
IRAK-4 and TRAF6 (Kawai et al., 2004; Honda et al., 2004). Overexpression of IRF7 
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leads to the activation of IFNα and IFNβ–inducible promoters and CpG stimulation of 
pDC derived from IRF7-/- mice resulted in a severely reduced IFN induction (Kawai et 
al., 2004; Honda et al., 2005). IRAK1 was shown to phosphorylate IRF7 and 
consistently, IRAK1-/- pDC fail to phosphorylate IRF7 in response to TLR9 agonists     
(Uematsu et al., 2005). Recently, a similar role as IRAK-1 was described for IKKα, 
although it remains unclear whether or not IKKα cooperates with IRAK-1 (Hoshino et 
al., 2006).  Taken together, these findings establish IRF7 and IRAK- 1 as key factors 
in viral-induced IFN response in pDC. 
In contrast with pDC, bone-marrow-derived DCs depend on IRF1, and not 
IRF7, for efficiënt CpG-induced IFN production (Negishi et al., 2006). In addition, it 
was shown that IRF1 expression is upregulated by IFN-γ stimulation and gene 
induction of IL-12p35 and iNOS is severely impaired in IRF1-/- DC stimulated with 
IFN-γ and CpG. Since IL-12p35 and iNOS are genes under control of a NF-κB 
inducible-promoter, this suggests that IRF1 cooperates with NF-κB, forming an 
enhanceosome complex resulting in efficient transcription of the latter genes. 
Mechanistically, CpG stimulation induces association of IRF1 with the intermediate 
domain of MyD88, followed by phosphorylation of IRF1 and translocation to the 
nucleus. 
In analogy with IRF1, IRF5 was shown to interact with the intermediate domain 
of MyD88 (Takaoka et al., 2005). Analysis of IRF5-/- mice revealed the critical role of 
IRF5 in TLR signalling. Pro-inflammatory cytokine production upon TLR3, -4, -5, -7, -
9 agonist stimulation was severely reduced in macrophages and conventional DCs 
derived from IRF5-/- mice and consistently, these mice were highly resistant against 
endotoxin shock. Following CpG stimulation IRF5 gets activated by a so far 
unidentified kinase and translocates to the nucleus where it was shown to bind to 
interferon-stimulated response element (ISRE) motifs of the IL-12p40 promoter. In 
the nucleus, IRF5, in coordination with NF-κB, induces transcription of IL-12p40, 
TNF-α and IL-6. 
Finally, IRF8 was shown to be involved in TLR9-dependent gene induction. 
IRF8-/- pDC failed to produce pro-inflammatory cytokines upon TLR9 activation 
(Tsujimura et al., 2004). IRF8 was shown to activate IKKα/β, essential kinases for 
NF-κB activation. 
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Fig.6: IRFs in TLR signalling. (A) Trif-dependent signalling. Activation of TLR4 and TLR3 
leads to the recruitment of Trif, ultimately leading to phosphorylation and nuclear 
translocation of IRF3. (B) pDCs produce vast amounts of typeI IFNs upon viral infection. 
Activation of TLR7/8 or TLR9, leads to the recruitment of IRF7 to MyD88, followed by IRAK-1 
(and IKKα)-dependent phosphorylation. Next, activated IRF7 translocates to the nucleus to 
induce IFN type I gene transcription. (C) IRF5 as well associates with MyD88 but is involved 
in inflammatory cytokine induction by TLRs. Upon stimulation, IRF5 translocates to the 
nucleus, where it binds ISRE motifs in promoter regions of pro-inflammatory cytokines like IL-
12p40, TNF-α, and IL-6, and is thought to induce gene transcription in coordination with NF-
κB. (D) IFNγ stimulation upregulates IRF1 expression. Upon TLR9 stimulation, IRF1 interacts 
with MyD88, resulting in activation and nuclear translocation of IRF1. In the nucleus, IRF1 
induces IFN-β and cooperates with NF-κB to induce iNOS and IL-12p35. 
 - 70 -
Taken together, these findings prove that IRF proteins are essential 
components of TLR-mediated responses.  The use of a whole spectrum of IRFs 
provides a basis for TLR specificity, which is based on cell type specific expression of 
IRFs, different activation pathways and differences in induced genes. 
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CHAPTER 3: Negative regulation of Toll-Like receptor signalling 
 
I.  Introduction  
 
TLR signalling leads to the production and secretion of pro-inflammatory 
cytokines, resulting in a potent immune reaction against invading pathogens. 
However, uncontrolled TLR activation and concomitant excessive inflammation is 
extremely harmful for the host. Deregulation of TLR signalling is observed in several 
autoimmune diseases, chronic inflammation and bacterial sepsis. Hence, TLR 
signalling balances on the tight rope, hovering between inordinate inflammation and 
potent pathogen clearance.  
Mammals have evolved several mechanisms that dampen the innate immune 
response, preventing sustained and toxic inflammation.  Attenuation of TLR signalling 
is achieved either by inhibiting ligand binding, by downregulation of TLR expression 
or by interference of downstream signalling (Fig.1). Thus, this multileveled regulation 
ensures an efficient attenuation of excessive TLR responses. 
 
Decoy receptors 
 
Extracellular modulation of TLR signalling is mediated by soluble decoy Toll-
Like receptors (sTLRs), directly inhibiting ligand recognition. Two sTLRs have been 
reported, sTLR4 and sTLR2.  sTLR4 is generated by alternative splicing and is 
upregulated upon LPS stimulation (Iwami et al., 2000). Overexpression of sTLR4 in 
macrophages drastically reduced LPS-induced TNF-α production and NF-κB 
activation. sTLR4 attenuates signalling by inhibiting the interaction of TLR4 with MD-
2 and CD14, resulting in a loss of LPS sensing (Hyakushima et al., 2004).  
sTLR2, on the other hand, is formed by ectodomain shedding of TLR2. Blood 
monocytes constitutively produce sTLR2, but the kinetics of sTLR2 release increase 
upon cell stimulation (LeBouder et al., 2003). sTLR2 reduces lipopeptide-induced NF-
κB activation and IL-8 secretion through competition with membrane-anchored TLR2 
for ligand (Iwaki et al., 2002).  
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Fig.1: Negative regulators of Toll-Like receptor signalling. TLR signalling is attenuated at 
multiple levels. Decoy receptors (sTLR2/sTLR4) prevent ligand sensing, whereas Triad3a 
and TGF-β downregulate TLR expression. The transmembrane molecules RP105, SIGIRR, 
ST2L and TRAIL-R inhibit TLR signalling by inhibiting ligand binding, sequestering adaptor 
molecules or direct interference of downstream signalling respectively. TLR adaptors are 
also targeted for negative regulation. Mal is downregulated by SOCS-1, Trif by Sarm and by 
TRAF1/4 and MyD88 by Fliih and MyD88s. Downstream IRAK kinases are inhibited by splice 
variants IRAK1c/2c/2d and by IRAK-M, Tollip and TRAF4. Activity of TBK1, a kinase involved 
in the MyD88-independent signalling pathway is modulated by SHP-2. TRAF6 is subjected to 
negative feedback by association of A20, TRAF4 and β-arrestins whereas ABIN-3 acts 
downstream of TRAF6. Finally, transcription factors NF-κB and IRF3 are inhibited by 
respectively Bcl-3/ATF3 and Pin-1. 
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   Inhibition of TLR expression 
 
 Overexpression of the RING finger protein Triad3A, a E3 ubiquitin-protein 
ligase, enhances proteolytic degradation of TLR4 and TLR9 and results in significant 
reduction of membrane expression and signalling (Chuang and Ulevitch, 2004).  
Recently, Triad3A was shown to target some intracellular signalling components, like 
RIP1 and the TLR adaptor molecules Mal and Trif to the proteasome, expanding its 
radius of action (Fearns et al., 2006). 
 Moreover, TLR expression can be modulated by anti-inflammatory cytokines 
like transforming growth factor β1 (TGF-β1). Elevated levels of TLR4 mRNA 
accompanied with hyperresponsiveness to LPS was observed in TGF-β1-/- mice 
(Cartney-Francis et al., 2004). Following TLR stimulation, TGF-β1 suppresses NF-κB 
activation, by facilitating proteasomal degradation of MyD88, further highlighting its 
role in TLR regulation (Naiki et al., 2005). 
 
Membrane-anchored regulators 
 
Over the past years several transmembrane TLR modulators were described. 
These proteins attenuate TLR signalling either by sequestering adaptor molecules, 
by inhibiting ligand binding or by direct interference of downstream signalling. One of 
them, single immunoglobulin IL-1R-related protein (SIGIRR), is composed of a single 
immunoglobulin domain and a cytoplasmic TIR domain. SIGIRR is expressed in 
epithelial cells and DCs, but not on macrophages, endothelial cells or fibroblasts 
(Wald et al., 2003). SIGIRR-deficient mice are more susceptible to endotoxic shock 
and DCs derived from these mice show enhanced activation in response to IL-1, 
LPS, CpG DNA but not to poly(I:C). Upon IL-1 treatment, SIGIRR interacts with IL-
1R, IRAK-1 and TRAF6, hinting SIGIRR inhibits IL-1R signalling by sequestering 
downstream signalling molecules.  In addition, SIGIRR was also shown to interact 
directly with TLR4, which might point to an analogous inhibitory mechanism.  
In analogy, another member of the TIR superfamily, ST2L, negatively 
regulates IL-1R and TLR4 signalling. ST2L was shown to sequestrate MyD88 and 
Mal trough its TIR domain, thereby inhibiting interaction of these TLR adaptors with 
TLR4 (Brint et al., 2004). 
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Radioprotective 105 (RP105) consist of a LRR homologous to TLR4 and a 
short intracellular domain. It was originally identified as a B cell-specific protein, but is 
also expressed in monocytes and myeloid DCs. RP105 associates with MD-1, and 
this RP105/MD-1 complex interacts with the TLR4 signalling complex, thereby 
sequestering LPS binding sites (Divanovic et al., 2005a; Divanovic et al., 2005b).    
Finally, TNF-related apoptosis-inducing ligand receptor (TRAIL-R), a member 
of the TNFR superfamily, was shown to be involved in TLR regulation. TRAIL-R-/- 
mice were less susceptible to MCMV infection which corresponded with augmented 
levels of IL-12, IFN-α, and IFN-γ. Moreover, stimulation of TLR-2, -3, and -4 
upregulated the expression of TRAIL, the transmembrane ligand of TRAIL-R, and 
enhanced cytokine production in TRAIL-R-/- macrophages. TRAIL-R stabilizes IκBα, 
preventing nuclear translocation of NF-κB and as a result inhibiting TLR-induced 
cytokine production (Diehl et al., 2004). Since both TRAIL and its receptor are 
transmembrane proteins, cell-cell contact is required for TRAIL-R function, adding an 
additional dimension to negative feedback mechanisms of TLR signalling. 
 
Intracellular regulators 
 
The importance of a tight control of TLR signalling is probably most reflected 
by the number of different intracellular regulators. For each step in the signal 
cascade, one or more inhibitors are described.  A first group of regulating molecules 
interferes with the stability or function of TLR adaptors. MyD88s(hort), a LPS-induced  
splice variant of MyD88 which lacks the intermediate domain bridging the DD to the 
TIR domain, was shown to inhibit LPS-induced NF-κB activation (Burns et al., 2003). 
MyD88s fails to recruit IRAK-4, thereby preventing phosphorylation and thus 
activation of IRAK-1. However, overexpression of MyD88s still resulted in JNK 
phosphorylation and activator protein 1 (AP-1)-dependent reporter gene induction, 
indicating that alternative splicing could play a role in the fine-tuning of TLR 
responses (Janssens et al., 2003). 
Sterile alpha and HEAT-Armadillo motifs containing protein (Sarm), is a 690aa 
TIR-domain containing molecule. The C. elegans ortholog of Sarm, TIR-1, has a 
critical function in fungal defence. Recently however, human Sarm has been 
assigned a role in negative regulation of Trif-dependent responses (Carty et al., 
2006). Overexpression of Sarm inhibits Trif-dependent activation of NF-κB and IRF3 
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while silencing of endogenous Sarm expression resulted in elevated cytokine and 
chemokine production following LPS and poly(I:C) stimulation. Sarm expression is 
highly upregulated by LPS stimulation, leading to a fast downregulation of Trif-
dependent signalling. The hypothesis for this negative feedback loop was further 
supported by the enhanced association of Trif and Sarm after LPS stimulation.   
Proteomic analysis of lipid A –stimulated macrophages identified Flightless I 
homolog (Fliih) as a possible MyD88-interacting molecule. Overexpression of Fliih 
exerted an inhibitory effect on LPS and Lipid A-induced NF-B activation and siRNA 
studies in Hek293 cells confirmed this regulatory role of Fliih in TLR4 signalling. Two-
hybrid analysis and co-immunoprecipitation studies further revealed that Fliih 
interacts with TIR domains of both MyD88 and TLR4, thereby directly interfering with 
TLR4-MyD88 complex formation in a LPS-dependent way (Wang et al., 2006a).  
The SOCS protein family consists of eight members: SOCS1 to SOCS7 and 
CIS. These proteins regulate JAK-STAT signalling, activated by cytokines. Cytokine 
receptor activation induces SOCS expression, thereby preventing prolonged 
activation (Starr et al., 1997). All SOCS members are composed of a central Src 
homology (SH2)-domain, involved in interaction with phosphotyrosine motifs in 
receptors and signalling molecules and a C-terminal SOCS-box, essential for the 
recruitment of the ubiquitin machinery. Next to its regulatory role in cytokine 
signalling, SOCS proteins also regulate some JAK-STAT-independent pathways like 
insulin, TNF-α and TLR signalling (Morita et al., 2000; De Sepulveda et al., 1999; 
Kawazoe et al., 2001). SOCS1-deficient mice were highly susceptible to LPS-induced 
sepsis and no endotoxin tolerance was observed (Kinjyo et al., 2002; Nakagawa et 
al., 2002). Additionally, SOCS1-/- macrophages produce increased levels of nitric 
oxide and pro-inflammatory cytokines in response to LPS and SOCS1 
overexpression suppresses LPS-induced NF-κB activation in macrophages. 
Moreover, SOCS expression is induced upon TLR stimulation (Stoiber et al., 1999; 
Dalpke et al., 2001; Baetz et al., 2004). Taken together, these data suggested a role 
for SOCS1 as negative regulator of TLR signalling, although no direct target of 
SOCS1 could yet be identified.  However, two groups reported that SOCS1 has an 
indirect inhibitory effect on TLR signalling, targeting the secondary type I IFN 
signalling pathway and not the main NF-κB pathway (Baetz et al., 2004; Gingras et 
al., 2004). Recently, a molecular basis for TLR regulation by SOCS1 was described. 
Upon TLR2 or TLR4 activation, Mal is phosphorylated by Bruton’s tyrosine kinase, 
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leading to its association with SOCS1. Subsequently, SOCS1 induces 
polyubiquitination of Mal, leading to its proteasomal degradation (Mansell et al., 
2006).   
 
Yeast two-hybrid analysis revealed interaction of the C-terminal domain of 
TRAF1 with the TIR domain of Trif. Overexpression of Trif caused caspase-8-
dependent cleavage of TRAF1. The cleaved N-terminal but not the C-terminal Trif-
binding part of TRAF1 inhibits TLR3- and Trif-mediated NF-κB and IRF3 activation. 
Thus, Trif-induced cleavage of TRAF1 seems required for abolishing Trif signalling 
(Su et al., 2006). Another member of the TRAF family, TRAF4, interacts with Trif, 
IRAK1 and TRAF6 and overexpression of TRAF4 leads to the specific inhibition of 
TLR-induced NF-κB and IRF3 activation, but did not affect TNFR signalling 
(Takeshita et al., 2005). These results indicate that next to the crucial role of TRAF6 
and TRAF3 in activation of NF-κB, other TRAF proteins are involved in negative 
regulation.  
 
Downstream kinases are targeted for negative regulation as well. IRAK-M, a 
member of the IRAK serine/threonine kinase family, is upregulated following TLR 
activation, alluding a regulatory function (Kobayashi et al., 2002). Contrary to IRAK-1 
and IRAK-4, IRAK-M lacks kinase activity and its expression is limited to monocytes 
and macrophages (Wesche et al., 1999). IRAK-M-/- cells responded much stronger to 
TLR stimulation and similarly, IRAK-M-/- mice exhibited a lowered endotoxin tolerance 
compared to wild type littermates (Kobayashi et al., 2002). Mechanistically, IRAK-M 
prevents dissociation of IRAK-1 and IRAK-4 from the activated TLR complex, and as 
such inhibits IRAK-1-TRAF6 complex formation. 
Analogous to MyD88s, some splice variants of IRAK-1 and IRAK-2 are also 
involved in TLR regulation.  Contrary to IRAK-1, IRAK-1c lacks kinase activity and 
cannot be phosphorylated by IRAK-4 (Rao et al., 2005). IRAK-2c and IRAK-2d on the 
other hand lack a DD, preventing MyD88 association (Hardy and O'Neill, 2004). 
Toll-interacting protein (Tollip) was the first described intracellular regulator of 
TLR signalling. Originally, it was identified as an IL-1R accessory protein-binding 
protein using a two-hybrid screen and appears to be involved in recruitment of IRAK-
1 to the activated IL-1R complex (Burns et al., 2000). Moreover, a role for Tollip in 
endosomal targeting of the IL-1R is described (Brissoni et al., 2006). Overexpression 
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of Tollip also downregulates TLR2 and TLR4-induced NF-κB activation (Zhang and 
Ghosh, 2002). Next to TLR2 and TLR4 binding, it also interacts with IRAK-1. This 
association is dependent on the phosphorylation status of both proteins: TLR-
induced autophosphorylation of IRAK1 leads to the phosphorylation of Tollip, 
resulting in a dissociation of the Tollip/IRAK1 complex and facilitating ubiquitination 
and degradation of IRAK1. 
Downstream kinases of the MyD88-independent pathway are also subjected 
to negative regulation. Recently, SH-2 containing protein tyrosine phosphatase-2 
(SHP-2), a widely used tyrosine phosphatase, was described as a specific regulator 
of TLR3 and TLR4 signalling (An et al., 2006). SHP-2 inhibits TLR3-induced pro-
inflammatory cytokine production, independently of its phosphatase activity. 
Moreover, SHP-2 deficiency results in upregulation of TNFα and IFNβ expression 
upon poly(I:C) and LPS treatment. Immunoprecipitation studies revealed that SHP-2 
directly binds the kinase domain of TBK-1, which could account for the SHP-2-
dependent inhibition.   
 
 Next to TRAF4, some other inhibitors of TRAF6 are described. These 
regulators interfere in the polyubiquination of TRAF6, an indispensable step for TLR-
induced NF-κB activation. A20, a TNF- and LPS-inducible de-ubiquitinating protein, 
binds TRAF6, thereby directly removing ubiquitin moieties from TRAF6 and inhibiting 
its function. In vivo experiments in A20-/- mice established the importance of A20 in 
endotoxin tolerance (Boone et al., 2004). 
Recently, a new member of the A20-binding inhibitors of NF-κB (ABINs) was 
identified (Wullaert et al., 2007). In analogy with ABIN-1 and ABIN-2, ABIN-3 inhibits 
TNF and IL-1 induced NF-κB activation. However, much in contrast with other ABINs, 
ABIN3 expression is enhanced upon LPS stimulation, suggesting a role as negative 
regulator of TLR4 pathway. In vitro, overexpression of ABIN-3 resulted in a decrease 
of LPS-induced NF-κB activation and co-expression studies further revealed that 
ABIN-3 inhibits TLR4-dependent gene expression downstream of TRAF6 but 
upstream of IKKβ. Moreover, adenoviral gene transfer of ABIN-3 in mice partially 
protected them against a lethal dose of LPS.    
β-arrestins are proteins involved in endocytosis of G-protein coupled receptors 
(GPCRs), leading to signal attenuation. In addition, they function as scaffold proteins 
for GPCR-induced activation of MAP kinases. Two members of the β-arrestin family, 
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β-arrestin-1 and -2, are involved in TLR signalling, exerting somewhat ambiguous 
functions. Both arrestins were shown to directly bind TRAF6, thereby preventing 
autoubiquitination of TRAF6 and as a result inhibiting NF-κB and AP-1 activation 
(Wang et al., 2006b). Much in contrast with this negative regulatory function, β-
arrestin-2 was shown to positively regulate ERK-1/2 activation and IL-6 production. 
Moreover, both β-arrestins upregulated LPS-induced IL-8 expression. Thus, further 
investigations are needed to clarify the precise functions of β-arrestins in TLR 
signalling pathways.  
 
Likewise, transcription factors are susceptible to negative feedback. Activation 
of one of them, IRF3, depends on phosphorylation induced by TLR3 or TLR4 
stimulation. Phosphorylation of the Ser339-Pro340 motif results in the association 
with peptidyl-prolyl-isomerase (Pin1). This interaction induces polyubiquitination and 
subsequent proteasomal degradation of IRF3, thereby blocking IFN responses 
(Saitoh et al., 2006).  
Expression of IRF4, another member of the IRF family, is upregulated by TLR 
activation, suggesting a regulatory function in TLR signalling. TLR-induced 
production of pro-inflammatory cytokines is enhanced in peritoneal macrophages 
derived from IRF4-/- mice and these mice are hypersensitive to DNA-induced shock. 
At a molecular level, IRF4 was shown to compete with IRF5, but not with IRF7 for 
MyD88 association, resulting in inhibition of IRF5-dependent pro-inflammatory gene 
expression (Negishi et al., 2005). 
System biology approaches led to the identification of activating transcription 
factor 3 (ATF3), a member of the ATF/CREB family of transcription factors, as a 
negative regulator of TLR signalling (Gilchrist et al., 2006). Transcription and 
production of IL-6 and IL-12 was markedly enhanced in ATF3-/- macrophages 
stimulated with LPS. ATF3 inhibits IL-6 and IL-12 transcription by altering chromatin 
structure in their promoter region, thereby preventing access of NF-κB and AP-1.  
Bcl-3, a nuclear member of the IκB family, interacts and stabilizes 
transcriptional inactive p50 homodimers. A recent study revealed that Bcl3-/- mice 
were hyperresponsive to TLR stimulation and septic shock (Carmody et al., 2007). 
Moreover, Bcl-3 was shown to be induced upon LPS stimulation, further adding to a 
possible regulatory role for Bcl-3 in TLR signalling. Mechanistically, Bcl-3 prevents 
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ubiquitination and degradation of promoter-associated p50 homodimers, thereby 
blocking access for transcriptional active NF-κB heterodimers. 
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CHAPTER 4: TLR signalling in infectious and non-infectious 
diseases 
 
 
Toll-Like receptors are crucial components of the first-line defence against 
invading pathogens. It is therefore not surprising that aberrant TLR signalling leads to 
severe disease conditions. Uncontrolled TLR activation will lead to a massive 
production of pro-inflammatory cytokines, and could eventually lead to septic shock, 
whereas reduced signalling could lead to a higher prevalence of bacterial or viral 
infection. However, due to its central position in the interface between innate and 
adaptive immunity, TLRs are also involved in pathologies unrelated to host defence. 
These diseases include severe autoimmune diseases like systemic lupus 
erythematosus or rheumatoid arthritis, asthma, several cardiovascular diseases and 
even some neuropathologies. The following part summarizes the genetic evidence 
linking TLRs with the abovementioned diseases. The role of TLR signalling in 
atherosclerosis, a common disease in western society, is further enlightened. In 
addition, an overview is given how TLR signalling can be exploited to generate 
therapeutics for these diseases.         
 
 
I. TLR Polymorphisms associated with pathogenesis 
 
Single nucleotide polymorphisms (SNPs) are found in almost every TLR gene 
and in several downstream mediators, and some of these can be linked with 
increased or in some cases reduced susceptibility to infectious as well as non-
infectious diseases (Table 1). These SNPs can be located either in the promotor 
region, the introns or the exons of the gene. SNPs affecting the aa sequence of the 
TLR are found in both the TLR ectodomain as well as the intracellular TIR domain. 
One of the most extensively studied polymorphism is a co-segregating missense 
mutation (D299G and T399I) in the extracellular domain of TLR4, which can be found 
in approximately 5- 10 % of the total population. Patients bearing these patients were 
shown to be hyporesponsive to inhaled endotoxin and an increased susceptibility to 
septic shock was observed (Arbour et al., 2000). Over the years, susceptibility to 
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several diseases was shown to be associated with these TLR4 polymorphisms. A 
well-documented disease condition affected by these SNPs is respiratory syncytial 
virus (RSV) infection. For long time it was known that RSV fusion protein also triggers 
TLR4 (Kurt-Jones et al., 2000). Moreover, it has been demonstrated that a functional 
TLR4 is indispensable for efficient clearance of RSV in mice (Kurt-Jones et al., 2000). 
Therefore, it came not as a surprise that several studies demonstrated a clear 
association of these TLR4 SNPs with an increased risk for RSV infection in infants 
(Awomoyi et al., 2007; Tal et al., 2004; Tulic et al., 2007). Others disease conditions 
linked to this TLR4 D299G and T399I polymorphism include a higher susceptibility 
towards malaria (Mockenhaupt et al., 2006), resistance to Legionnaires' disease 
(Hawn et al., 2005a), increased risk of prostate cancer (Cheng et al., 2007) and 
systemic inflammatory response syndrome (Child et al., 2003). 
 A recently described polymorphism in TLR1, TLR1I602S, exhibits some 
interesting characteristics.  This TLR1 polymorphism is associated with aberrant 
trafficking of the receptor to the cell surface (Johnson et al., 2007). As a result 
inflammatory responses to bacterial lipopeptides are impaired (Hawn et al., 2007; 
Johnson et al., 2007). Surprisingly, a lower incidence of leprosy is observed in 
persons carrying the I602S allele (Johnson et al., 2007). These findings indicate that 
recognition of Mycobacterium leprae by TLR1/TLR2 is an essential step in the 
immune evasion of this pathogen.   
Two polymorphisms in the TIR domain of TLR2, R753Q and R677W, 
respectively are associated with an increased susceptibility to tuberculosis and  a 
higher risk of lepromatous leprosy (Ogus et al., 2004; Kang et al., 2002). 
 In addition, polymorphisms in TLR3, TLR5, TLR6, TLR7, TLR9 and CD14 are 
associated with several disease states (Verstak et al., 2007). 
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Gene SNP Associated condition/disease Reference 
    
    
TLR1 Pro315Leu Impaired response to bacterial cell wall components (Omueti et al., 2007) 
    
 Ile602Ser Impaired cell surface trafficking and functional response / Protection against leprosy 
(Johnson et al., 
2007; Hawn et al., 
2007) 
    
    
TLR2 T-16933A Increased prevalence of Gram-positive bacterial cultures and sepsis 
(Sutherland et al., 
2005) 
    
 Arg677Trp Increased susceptibility to lepromatous leprosy (Kang et al., 2002; Bochud et al., 2003) 
  Increased susceptibility to tuberculosis in Tunisian patients (Ben-Ali et al., 2004) 
    
 Arg753Gln Predisposition to staphylococcal infection (Lorenz et al., 2000) 
  Association with urinary tract infection in children (Tabel et al., 2007) 
  Enhanced risk of developing tuberculosis (Ogus et al., 2004) 
  Association with acute rheumatic fever in children (Berdeli et al., 2005) 
  Association with susceptibility to recurrent bacterial infections 
(Kutukculer et al., 
2007) 
    
    
TLR3 
C2593T/C2642A/ 
A2690G (intron 
3) 
Association with type I diabetes in South African blacks (Pirie et al., 2005) 
    
 Asn284Ile/Leu412Phe Reduced expression and activity  
(Ranjith-Kumar et 
al., 2007) 
    
 T299698G (exon 3) 
Association with Stevens-Johnston syndrome in Japanese 
population 
(Ueta et al., 2007) 
    
    
TLR4 Asp299Gly Decreased risk of carotid artery atherosclerosis (Kiechl et al., 2002) 
  Premature birth (Lorenz et al., 2002a) 
  Increased severity of systemic inflammatory response syndrome 
(Child et al., 2003) 
  Lower susceptibility to myocardial infarction and cardiovascular events 
(Holloway et al., 
2005; Boekholdt et 
al., 2003) 
  Higher prevalence of asthma (Fageras Bottcher et al., 2004) 
  Possible protection against late-onset Alzheimer’s disease (Minoretti et al., 2006) 
 
 Asp299Gly/ Thr399Ile 
Association with symptomatic respiratory syncytial virus 
infection in infants 
(Awomoyi et al., 
2007; Tal et al., 
2004) 
  Endotoxin hyporesponsiveness  (Arbour et al., 2000; Lorenz et al., 2002b) 
  Association with ulcerative colitis and Crohn’s disease 
(Torok et al., 2004a; 
Franchimont et al., 
2004) 
  Association with periodontal disease (Schroder et al., 2005) 
  Reduced prevalence of diabetic neuropathy in patients with type 2 diabetes 
(Rudofsky, Jr. et al., 
2004) 
  Resistance to Legionnaires' disease (Hawn et al., 2005a) 
  Increased risk of prostate cancer (Cheng et al., 2007) 
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TLR5 Arg392STOP Association with susceptibility to Legionnaires’ disease (Hawn et al., 2003) 
  Resistance to systemic lupus erythematosus (Hawn et al., 2005b; Demirci et al., 2007) 
  Heterozygous carriage protects against Crohn’s disease in Jewish subjects 
(Gewirtz et al., 2006) 
    
    
TLR6 Ser249Pro Decreased risk for asthma  
(Tantisira et al., 
2004; Hoffjan et al., 
2005) 
    
    
TLR7 c.1-G120T  (intron 1) 
Protection against advanced inflammation and fibrosis in 
chronic male HCV patients 
(Schott et al., 2007) 
    
    
TLR9 T-1237C (promotor) Association with Crohn’s disease  
(Torok et al., 2004b) 
  Putative association with atopic eczema (Novak et al., 2007) 
    
 
T-1237C /T-
1486C 
(promotor) 
Creation of new potential transcription factor binding sites  (Hamann et al., 2006) 
    
 A1174G (intron 1) 
Predisposition to systemic lupus erythematosus in humans 
homozygous to G allele 
(Tao et al., 2007) 
    
 
A1174G (intron 
1)/ A1635G 
(exon 2, 
Pro545Pro) 
Rapid progression of HIV-1 infection (Bochud et al., 2007) 
    
Table 1: TLR receptor polymorphisms and associated conditions. 
 
Downstream signalling adaptors are in a varying degree polymorphic. Mal is 
the most polymorphic adaptor, and no amino acid altering variations are described for 
Tram and Trif (Sheedy and O'Neill, 2007).  A study by Hawn et al. described 4 Mal 
polymorphisms present in Vietnamese tuberculosis patients (Hawn et al., 2006). One 
synonymous mutation (C558T; A186A) was associated with increased susceptibility 
for tuberculosis. Additionally, TLR2, but not TLR4 agonist stimulation of blood cells of 
patients homozygous for this mutation, resulted in a decrease in IL-6 production. 
However, it remains unclear how this variant, of which the aa sequence is not altered, 
can exhibit a different phenotype and linkage with other functional mutations 
therefore cannot be excluded. Another study, performed by Khor and colleagues, 
described a S180L Mal variant, of which heterozygous carriage is associated with 
protection against tuberculosis, bacteremia, malaria and pneumococcal disease 
(Khor et al., 2007). Biochemical analysis revealed that MalS180L still interacts with 
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MyD88 and Mal, but is not capable of TLR2 binding. Since homozygous MalS180L 
individuals are rarely found, and homozygosity is associated with increased 
susceptibility for invasive pneumococcal disease, Khor et al. hypothized that 
MalS180L heterozygosity results in an optimal intermediate immune response. 
In addition, IRAK4 and NEMO/IκBα mutations are linked to respectively 
increased Gram-positive infections and X-linked anhidrotic ectodermal dysplasia with 
immunodeficiency (Picard et al., 2003; Courtois et al., 2003; Medvedev et al., 2003). 
 
II. Involvement of Toll-Like receptor signalling in 
atherosclerosis 
 
 
Atherosclerosis is characterized by a chronic inflammatory response in the 
walls of arteries, resulting in the accumulation of lipids and inflammatory cells in the 
subendothelial space (Libby, 2002). Atherosclerosis is initiated by the retention and 
aggregation of circulating lipids onto the vessel wall (Skalen et al., 2002).  This event 
results in inflammatory cells infiltration and unregulated lipid uptake by macrophages. 
Next, these lipid loaded macrophages or foam cells accumulate and mature into 
lesions characterized by smooth muscle cell infiltration, extracellular matrix formation, 
calcification and necrosis. Rupture of these lesions can result in an artery-blocking 
thrombus which can provoke a myocardial infarction or stroke (Bjorkbacka, 2006).  
Elevated levels of plasma lipids are fundamental for the development of 
atherosclerosis. In addition, a growing number of reports link Toll-Like receptors 
signalling to disease development. These recent findings will be summarized 
throughout the following section. 
 
The first evidence linking Toll-Like receptors and atherosclerosis arose from 
the observation that various TLRs were expressed in atherosclerotic lesions, mostly 
on infiltrated macrophages and endothelial cells (Edfeldt et al., 2002). Recent bone-
marrow transplantation experiments in mice suggested that only TLRs expressed on 
cells not of bone-marrow origin contribute to lesion progression (Mullick et al., 2005). 
In addition it was shown that vascular endothelial cells do not express the adaptor 
Tram (Harari et al., 2006). These data suggest that TLR-induced progression of 
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atherosclerosis primary depends on the MyD88-dependent pathways in endothelial 
cells.  
The role of TLR signalling in atherosclerosis was further highlighted by the 
connection of a TLR4 polymorphism which abrogates signalling, TLR4 Asp299Gly, 
with decreased susceptibility to atherosclerosis and a lower risk to myocardial 
infarction and cardiovascular events (Kiechl et al., 2002; Holloway et al., 2005). 
 The most compelling evidence arose from knockout experiments in 
atherosclerosis mouse models. Targeted deletion of MyD88 or TLR4  in ApoE-/- mice 
resulted in a clear reduction of aortic plaques  (Michelsen et al., 2004).  Additionally, 
knockout experiments with the atherosclerosis-prone mouse strain Ldlr-/-  revealed a 
role for TLR2 in disease progression (Mullick et al., 2005).  
The exact nature of TLR ligands inducing atherosclerosis remains unclarified 
since both exogenous, derived from pathogens such as HSV or Chlamidia 
pneumoniae as well as endogenous TLR ligands, like minimally modified LDL (MM-
LDL), were shown to influence disease onset (summarized in Michelsen and Arditi, 
2006).   At a molecular level these ligands induce a variety of cell-type dependent 
responses. These include pro-inflammatory cytokine and chemokine secretion, 
upregulation of adhesion molecules, secretion of matrix metalloproteases, involved in 
the degradation of the extracellular matrix and intitiating the adaptive immune 
response (Bjorkbacka, 2006).  
 Another TLR-dependent process based on inhibition of Liver X receptor (LXR) 
activity could as well influence atherosclerosis progression. LXRs are transcriptional 
regulators of genes like ABCA1 and ABCG1 that promote cholesterol efflux in foam 
cells via reverse cholesterol transport. Synthetic LXR ligands were shown to reduce 
atherosclerosis and loss of LXR expression dramatically contributes to disease 
progression (Naik et al., 2006; Tangirala et al., 2002; Joseph et al., 2002). Various 
bacterial and viral pathogens inhibit LXR function and cholesterol efflux in foam cells 
through a Trif-dependent mechanism (Castrillo et al., 2003). This inhibition could 
trigger lipid accumulation and as a result accelerate atherosclerosis. 
These data provide conclusive evidence for the connection between TLR signalling 
and the progression of atherosclerosis and validates TLR signalling components as 
possible therapeutic targets for atherosclerotic drug development. 
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III. Therapeutic Targeting of TLR signalling 
 
 
During the past years, lots of effort is put in the development of therapeutics which 
modulate the innate immune system. The clinical applications of these drugs are 
versatile as discussed above: cancer, allergic diseases, infections and autoimmune 
diseases. The Toll-Like receptor family is keystone of this innate immunity and as a 
consequence forms a major target of this research. Both TLR agonists as well as 
TLR antagonists are assayed for their therapeutic potential.   
 
TLR agonists as vaccine adjuvants 
 
Activation of the innate immune system is primordial for efficient vaccination. 
Therefore vaccine adjuvants are co-administered that enhance antigen uptake by 
DCs, resulting in a long-lasting antigen-specific adaptive immune response. Recent 
findings revealed a clear link between innate and adaptive immune responses, which 
suggested the possibility of TLR agonists as vaccine adjuvants.  Currently, the 
adjuvant effect unmethylated CpG DNA (TLR9), LPS analogues (TLR4) and 
imidazoquinoline compounds (TLR7) in HBV, influenza and HIV vaccines are 
evaluated (Daubenberger, 2007; Wille-Reece et al., 2005; Dupont et al., 2006). 
Vaccination efficiency can further be enhanced by linkage of antigen to the TLR 
agonist, which increases the antigen uptake by DCs and by delivery in lipid 
emulsions, microparticles or virus-like particles (Kanzler et al., 2007).     
 
TLR agonists in treatment of allergic diseases 
 
Asthma and other allergic diseases are characterised by an inappropriate TH2-
response. Therefore, the effect of TLR4 and TLR9 agonist, which induce a potent 
TH1-response, was analysed in diverse asthmatic and allergic model systems. TLR 
induction resulted in a shift of TH2/TH1 ratio and consequently diminished allergic 
symptoms (Creticos et al., 2006; Gauvreau et al., 2006). Drugs based on TLR4/TLR9 
agonist combined with modified allergens successfully passed clinical trials and will 
be marketed soon.      
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TLR agonists and antiviral therapy 
 
Agonists of TLR3, TLR7/8 and TLR9 are currently being evaluated for the treatment 
of viral infections. Imiquimod, a TLR7 agonist, is already used in the treatment of 
genital warts caused by human papilloma virus (Chang et al., 2005). In addition, the 
therapeutic applicability of these agonists in HCV and HIV treatment is being assayed 
(Fletcher et al., 2006).  
 
TLR agonists in cancer therapy 
 
As mentioned above, TLR7 agonists are used for the treatment of some virus-
induced cancers. Additionally, innate immune activation by CpG DNA results in 
antitumor activity in rodent models of cancer. This activity is based on activated DC 
which boosts both NK cells and tumor-specific T cell responses. Promising results of 
these TLR9 agonists are obtained in clinical trials for colorectal cancer, lung cancer 
and non-Hodgkin’s lymphoma (Kanzler et al., 2007; Paul, 2003). 
 
TLR antagonists as therapeutic tool 
 
In contrast to the therapeutic use of TLR agonists, studies concerning the 
appropriateness of TLR antagonists in the treatment of inflammatory disorders did 
not lead to drug development so far. However, the potency of some TLR antagonists 
is apparent. Currently, only the extracellular part of TLRs is targeted either by the use 
of neutralising antibodies or by the use of structural analogues of TLR agonists, 
capable of binding the receptor but inhibiting further signalling (Meng et al., 2004; 
Bennett-Guerrero et al., 2007). At present, two antagonistic analogues of Lipid A, the 
TLR4-activating part of LPS, are currently in phase 3 trials for bacterial sepsis 
(Rossignol and Lynn, 2005).  Moreover, excessive non-bacterial inflammation, 
observed in some autoimmune diseases like Systemic lupus erythematosus, can be 
dampened by TLR7/TLR9 antagonists (Barrat et al., 2005). Growing evidence predict 
a therapeutic use of TLR antagonists in other inflammatory diseases, including 
atherosclerosis, asthma, rheumatoid arthritis and inflammatory bowel disease 
(Gearing, 2007).  
Next to targeting the TLRs, inhibition of downstream signalling molecules is also 
considered as a therapeutic target (Bartfai et al., 2003). Several peptides based on 
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the BB loop of the TIR domain of MyD88 were shown to block further signalling 
(Bartfai et al., 2003; Loiarro et al., 2007). However, the potency of these types of 
inhibitory components was not yet assayed in a clinical trial at present.    
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CHAPTER 5: Other pattern-recognition receptors 
 
I. Dectin-1 
 
 
Control of fungal infection is mediated by TLR2 and TLR4, which respectively 
recognize the yeast cell wall components zymosan/phospholipomannan and mannan 
(Jouault et al., 2003; Netea et al., 2006; Tada et al., 2002; Underhill et al., 1999). 
Recently however, other ‘fungi-sensing’ PRRs were identified (Brown, 2006; 
Dennehy and Brown, 2007). One of these, Dectin-1 is a member of the lectin-
receptor family and was shown to detect β-1,3-glucan, which represents up to 50% of 
the fungal cell wall  (Brown and Gordon, 2001; Palma et al., 2006). Extracellularly it is 
composed of a ligand binding single C-type lectin-like domain while an intracellular 
ITAM (immunoreceptor tyrosine-based activation)-like motif is responsible for further 
signal transduction. Originally, Dectin-1 expression was thought to be restricted to 
dendritic cells (Ariizumi et al., 2000), but high levels of Dectin-1 can also be found on 
macrophages, B and T lymphocytes (Taylor et al., 2002; Willment et al., 2005).  
Fungal recognition by Dectin-1 results in the production and secretion of 
inflammatory cytokines, phagocytosis and oxidative burst (Rogers et al., 2005; 
Underhill et al., 2005; Herre et al., 2004).  
Signal transduction starting from Dectin-1 can be divided into a Syk (Spleen 
tyrosine kinase)-dependent and Syk-independent pathway (Fig.1). Fungal triggering 
of Dectin-1 leads to tyrosine phosphorylation of the ITAM-like motif, mediated by Src 
kinases, and the recruitment of Syk kinase through one of its SH2-domains. This 
activated Syk kinase is thought to activate phospholipase C-γ (PLC-γ), which 
produces diacylglycerol (DAG). Protein kinase C (PKC) is activated by this DAG and 
in turn activates Card 9 (Caspase-recruitment domain 9) (Dennehy and Brown, 2007; 
Gross et al., 2006; Hara et al., 2007). Phosphorylated Card 9 forms a docking site for 
the Bcl-10/MALT1 complex. This complex activates the IkB kinases leading to the 
activation of NF-κB and the induction of IL-10 and TNF-α. However, Dectin-1 
mediated phagocytosis of zymosan, a β–glucan rich particle of the yeast cell wall, 
does not require Syk kinase, but the exact mechanism remains to be elucidated 
(Underhill et al., 2005; Herre et al., 2004).  
 - 110 -
The importance of Dectin-1 in fungal control was further underscored by the 
generation of Dectin-1-/- mice, which were more susceptible to Candida albicans and 
Pneumocystis carini infections than their wild type littermates (Taylor et al., 2007), 
although these data could only partially be confirmed by another group (Saijo et al., 
2007).  
Next to Dectin-1, TLR signalling pathways are also involved in the mammalian 
control of fungal infection. Moreover, efficient production of pro-inflammatory 
cytokines including TNF-α and IL-12 requires both Dectin-1 and TLR2 (Gantner et al., 
2003; Brown et al., 2003). Although the exact mechanisms of this synergy remain 
unknown, the adaptor molecule TRAF6 likely provides a link between both signalling 
pathways (Dennehy and Brown, 2007).   
 
 
 
 
  
 
 
 
 
 
 
Fig.1: The Syk-dependent Dectin-1 
signalling pathway. β-1,3-glucan 
recognition by Dectin-1 leads to the 
phosphorylation of its intracellular 
ITAM-like motif, forming a docking 
site for Syk kinase. Subsequent 
activation of Syk kinase leads to the 
phosphorylation of Card9, which in 
turn recruits the Bcl-10/MALT1 
complex, resulting in the activation of 
NF-κB en the production of TNF-α 
and IL -10. 
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II. RIG-I-Like receptors 
 
 
The role of TLRs in antiviral response is well defined. TLR2 and TLR4 detect 
viral PAMPs at the cell surface whereas TLR3, TLR7/8 and TLR9 recognise different 
viral PAMPs in endosomes. Viral triggering of these TLRs results in the induction of 
type I interferons. However, replication of viruses in the cytoplasm can not be sensed 
by the TLR system. This void is filled by two cytoplasmic PRRs, retinoic-acid-
inducible protein I (RIG-I) and Melanoma differentiation associated gene 5 (Mda5) or 
Helicard (Yoneyama et al., 2004; Andrejeva et al., 2004). Both RIG-I and Mda5 are 
able to detect cytoplasmic dsRNA. N-terminally they are composed of two CARD 
domains, necessary for downstream signalling, and a C-terminal DExD/H box 
helicase domain, involved in dsRNA binding. The RIG-I homologue Lgp2 also 
contains this helicase domain but lacks the CARD domains, and acts as a negative 
regulator of RIG-I and Mda5 (Rothenfusser et al., 2005; Komuro and Horvath, 2006; 
Saito et al., 2007). 
Overexpression of RIG-I blocks replication of Vesicular Stomatitis Virus (VSV) 
and ECMV and conventional dendritic cells and fibroblasts of RIG-I-/- mice are unable 
to produce inflammatory cytokines and type I IFNs upon NDV, VSV and Sendai Virus  
infection (Kato et al., 2005; Kato et al., 2006; Yoneyama et al., 2005). Mda5 on the 
other hand seems to be important in the response against picornaviruses, like 
Encephalomyocarditis Virus (EMCV) and the synthetic dsRNA analogue poly(I:C) 
(Kato et al., 2006; Gitlin et al., 2006). RIG-I detects and directly binds the 5'-end of 
certain viral RNA genomes, in particular a 5'-triphosphate group. Such 5'-
triphosphates are generally removed from or capped in host RNA species, enabling 
discrimination between self and non-self RNA (Pichlmair et al., 2006; Hornung et al., 
2006). The binding properties of Mda5 on the other hand still remain elusive.   
RIG-I and Mda5 signal transduction starts with the recruitment through 
homotypical CARD domain interactions of the mitochondrion-associated protein 
‘interferon promoter stimulator’ (IPS-1), also known as virus-induced signalling 
adaptor (VISA), mitochondrial antiviral signalling protein (MAVS) or CARD adaptor 
inducing IFNβ (Cardif) (Kawai et al., 2005; Meylan et al., 2005; Xu et al., 2005; Seth 
et al., 2005) (Fig.2). Recently it was shown that this RIG-I/IPS-1 association, but not 
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the Mda5/IPS-1 interaction, depends on virus-induced ubiquitinylation of the RIG-I 
CARD domain by the ubiquitin ligase TRIM21 (Gack et al., 2007). The IPS-1 forms a 
branching point between two pathways either resulting in the induction of IRFs or NF-
κB. On the one hand, IPS-1 interacts with TRAF3, which in turn engages the 
TBK1/IKKi complex, resulting in the phosphorylation and activation of IRF3 and IRF7 
and ultimately leading to the production of type I IFNs (Saha et al., 2006; Kawai et al., 
2005).  On the other hand, IPS-1 is also able to interact with FADD and RIP-1 (Kawai 
et al., 2005; Balachandran et al., 2004). This results in the activation of IKK/NF-κB 
pathway and the production of inflammatory cytokines. Recently, a crucial role for 
caspase-8 and caspase-10 in dsRNA-induced NF-κB activation was described, 
although the mechanistics of their involvement remain to be elucidated (Takahashi et 
al., 2006).  
In analogy with viral dsRNA, viral dsDNA is also detected in the cytoplasm in a 
TLR-independent manner. The subsequent induction of type I IFNs seems to be 
dependent on IPS-1 and the IKKi/TBK1 complex but not on RIG-I, which suggested 
the existence of a cytoplasmic viral DNA-sensing PRR (Ishii et al., 2006). However, 
another group observed an IPS-1 independent IFN induction following viral DNA 
triggering (Sun et al., 2006). Recently, such a cytoplasmic DNA sensor was 
described (see below) (Takaoka et al., 2007), but further experiments are still  
needed to clarify the role of IPS-1 in cytoplasmic DNA-induced IFN production.    
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Fig.2: Cytoplasmic detection of viral RNA and DNA through RIG-I-Like receptors and 
IPS-1. Upon viral RNA sensing, RIG-I and Mda5 associate with the mitochondrion-
associated molecule IPS-1 through homotypical CARD domain interactions. Starting from 
IPS-1, two signalling cascades are activated ultimately leading to the activation of IRFs and 
NF-κB respectively. Activated IPS-1 engages TRAF3 and the TBK1/IKKi complex, resulting 
in phosphorylation and activation of IRF3 and IRF7. Additionally, IPS-1 activates the IKK/NF-
B pathway, a proces mediated by the FADD/RIP1 complex. Viral DNA is sensed by DAI, 
which results in the association with TBK1 and the activation of IRF3. 
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III. DAI 
 
 
 
Over the past years, several reports described the immunogenic nature of 
cytosolic DNA. Detection of this intracellular pathogenic DNA was shown to be TLR9-
independent and resulted in type I IFN induction (Hochrein et al., 2004; Ishii et al., 
2006; Stetson and Medzhitov, 2006). These findings suggested the presence of one 
or more cytosolic DNA sensors. Recently, Takaoka and colleagues described DNA-
dependent activator of IFN-regulatory factors (DAI) as a candidate DNA sensor 
(Takaoka et al., 2007). DAI was first reported as a gene induced in host tissues in 
response to tumours (Fu et al., 1999) and was later reported to bind Z-form DNA (Ha 
et al., 2006), although the functional relevance hereof remained elusive. FRET 
analysis and pull-down assays revealed a direct interaction between B-form DNA and 
DAI and this association induces DAI/TBK1/IRF3 complex formation, resulting in the 
activation of the latter (Takaoka et al., 2007). Consistently, knock-down of DAI 
abolished IRF3 activation and concomitant IFNβ gene induction in response to viral, 
bacterial, mammalian and B-form DNA, establishing the importance of DAI in DNA-
induced innate immune responses.   
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IV. NOD-Like receptors 
 
 
 
Intracellular pathogen invasion is, next to the RIG-I-like family of receptors, also 
monitored by a second group of cytosolic ‘pathogen-sensing’ proteins, the NOD-Like 
receptor (NLR) family (Martinon and Tschopp, 2005; Inohara et al., 2005). NLRs can 
be split up in two major sub-classes: the NOD (nucleotide-binding oligomerisation 
domain) group of proteins (NOD1-5) and the NALP (NACHT-, LRR-, and pyrin-
domain-containing proteins) series of proteins (NALP1-14). Three other proteins, 
IPAF, CIITA and NAIP5 complete the NLR family. All 22 NLR members contain C-
terminal LRRs, a nucleotide-binding and oligomerisation domain (NACHT domain) 
and an N-terminal effector domain (Fig.3). NOD receptors signal through CARD 
domains, while NALPs contain a Pyrin motif. NAIP5 is the only NLR using a string of 
3 baculoviral inhibitor of apoptosis repeats (BIRs) as a signalling domain.  Ligand 
binding to these NLRs induces NACHT-dependent oligomerisation, ultimately leading 
to the production of inflammatory cytokines and activation of caspase-1 and the 
inflammasome (Meylan et al., 2006). 
 
 
 
 
 
Fig.3: NOD-Like receptor 
family 
(adapted from (Meylan et al., 
2006)).  
Based on structural features, 
NOD-Like receptors are divided 
in two subclasses: NOD proteins 
(NOD1Æ5) and the NALP family 
(NALP1Æ14).  IPAF, CIITA and 
NAIP5 complete the NLR family.  
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1. NOD proteins 
 
NOD1 and NOD 2 both sense bacterial peptidoglycan (Girardin et al., 2003b; 
Girardin et al., 2003a; Viala et al., 2004), although the exact nature of their ligands 
differs. NOD2 detects muramyl dipeptide (MDP), which is found in the cell wall of 
both Gram-positive and Gram-negative bacteria.  NOD1, on the other hand, exerts a 
more restricted pathogen recognition pattern, as it responds to meso-diaminopimelic 
acid (DAP), which is limited to Gram-negative peptidoglycan.  Recognition of these 
ligands through their LRRs results in homo-oligomerisation and activation of NOD 
proteins and leads to a CARD-dependent recruitment of the serine-threonine kinase 
RIP2 or CARD9 and the subsequent activation of respectively NF-κB and MAPKs 
(Fig.4) (Viala et al., 2004; Hsu et al., 2007; Inohara et al., 2003).   
 The importance of NOD proteins in innate response becomes apparent by the 
growing number of autoimmune diseases linked to NOD polymorphisms. Mutations in 
the NOD2 gene are linked with severe inflammatory diseases such as Crohn’s 
disease, Blau syndrome and early-onset sarcoidosis. Moreover, predisposition to  
inflammatory bowel disease and asthma is observed in patients with NOD1 mutations 
(McGovern et al., 2005; Hysi et al., 2005). The precise role of NOD proteins in these 
disorders is far from understood, as contradictory effects of these mutations are 
observed (see box1).  
 
 
Fig.4: NOD signalling. NOD proteins 
recognize different parts of the bacterial cell 
wall component peptidoglycan; NOD1 binds 
meso-diaminopimelic acid (DAP) while NOD2 
senses muramyl dipeptide (MDP). Upon 
ligand recognition, NOD proteins associate 
with RIP2 and CARD9 through homotypic 
CARD domain interactions, leading to the 
activation of MAPK and NF-κB.    
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Text box:  Role of NOD2 in Crohn’s disease 
 
 Crohn’s disease is, next to ulcerative colitis, one of the two major forms of 
inflammatory bowel disease. It is characterised by severe intestinal inflammation, 
associated with increased production of TNF-α and IL-1β in the lamina propria. As a 
result, patients suffer from fever, abdominal pain, diarrhoea and weight loss.  
More than 60 NOD2 variants are reported, of which 3 mutant alleles (R702W, 
G908R and L1007fs) account for 50% of all patients (1). All three mutations affect the C-
terminal LRR region of NOD2 (a single amino acid is altered for R702W and G908R, 
whereas the L1007fs allele bears a frame-shift mutation, resulting in a truncated form of 
NOD2, of which the last 33 amino acids are missing. Heterozygosity for one of these 
mutated alleles, results in a 2- to 4 –fold increased risk for Crohn’s disease, whereas a up 
to 40-fold increase in risk is observed with homozygous patients (2). However, NOD2 
mutations are neither sufficient nor necessary to develop Crohn’s disease, as mutated 
NOD2 alleles are found in healthy individuals and 60%-70% of Crohn’s disease patients 
do not have a mutated form of NOD2. So, next to NOD2 mutations, other genetic and 
environmental factors are involved in Crohn’s disease pathogenesis (3). 
Cultured macrophages and monocytes from Crohn’s disease patients, homozygous 
for the NOD2L1007fs mutation, do not respond to muramyl dipeptide (MDP), the common 
NOD2 ligand (4). Moreover, macrophages of NOD2-/- mice neither produce IL-1β or TNF-β 
upon MDP stimulation (5). These data conflict with the severe inflammation observed in 
Crohn’s disease patients. However, macrophages derived from NOD2L1007fs knock-in mice, 
exhibit an increased level of NF-κB activation and pro-inflammatory cytokine production 
following MDP administration (6). Apparently, the molecular basis of NOD mutations as a 
predisposing risk factor for Crohn’s disease is far from elucidated, and interpretation is 
further complicated by the clear synergy between NOD2/NOD1 and NOD2/TLR signalling 
pathways (5, 7). 
 
 
 1.  L. Eckmann, M. Karin, Immunity. 22, 661 (2005). 
 2.  M. Economou, T. A. Trikalinos, K. T. Loizou, E. V. Tsianos, J. P. Ioannidis, Am. J Gastroenterol. 99, 2393 
(2004). 
 3.  T. Ahmad et al., Gastroenterology 122, 854 (2002). 
 4.  J. Li et al., Hum. Mol. Genet. 13, 1715 (2004). 
 5.  K. S. Kobayashi et al., Science 307, 731 (2005). 
 6.  S. Maeda et al., Science 307, 734 (2005). 
 7.  M. G. Netea et al., J Biol. Chem. 280, 35859 (2005). 
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2. NALP proteins 
  
 NALP proteins are major constituents of the multiprotein inflammasome 
complex. At present, fourteen human NALPS have been identified, but only two types 
of ‘NALP-inflammasomes’ are characterised (Martinon et al., 2002; Agostini et al., 
2004). The NALP1 inflammasome consists, next to NALP1, of Caspase-1/Caspase-5 
and Asc. (Apoptosis-associated spec-like protein containing a CARD), whereas the 
NALP3 inflammasome is composed of NALP3, Asc, Cardinal and Caspase-1. Asc is 
a central adaptor molecule in the inflammasome linking NALP with Caspase-1 
through homotypic CARD and Pyrin domain interactions. NALP3 misses, compared 
to NALP1, a C-terminal CARD and FIIND domain. This lack is by-passed through 
Cardinal, a molecule with an analogous domain structure as the C-terminal region of 
NALP1 (Fig.5).  
Not only PAMPs, like MDP from bacterial PG or bacterial and viral RNA, but 
also host danger signals can activate the NALP3 inflammasome (Martinon et al., 
2004; Kanneganti et al., 2006b; Kanneganti et al., 2006a). These danger-associated 
molecular patterns or DAMPs include K+ efflux, induced by high concentrations of 
ATP or the Staphylococcus aureus α-toxin, and monosodium urate crystals, a danger 
signal from dying cells (Martinon et al., 2006; Mariathasan et al., 2006). Anthrax 
lethal toxin, on the other hand, is the only activator of the NALP1 inflammasome 
known thus far (Boyden and Dietrich, 2006). Activation of the inflammasome complex 
leads to the caspase-1-dependent processing and secretion of the pro-inflammatory 
cytokines IL-1β and IL-18 and, at least in some cell types, to cell death (Petrilli et al., 
2005; Martinon et al., 2002). 
  Excessive or uncontrolled release of IL-1β results in systemic inflammation 
and periodic fever (Aganna et al., 2002; Agostini et al., 2004; Hoffman et al., 2001; 
Feldmann et al., 2002). Therefore, production, processing and secretion of IL-1β are 
strictly controlled processes (Burns et al., 2003). To elicit an efficient IL-1β release, at 
least two distinct danger signals are required. At first, TLR activation induces the 
production of pro-IL-1β, whereas a second stimulus, e.g. K+ efflux, activates the 
inflammasome. Thus, both an external as well as an internal stimulus are 
indispensable for IL-1β secretion, avoiding innate responses against commensals. In 
addition, different proteins, like COP, ICEBERG, INCA and pyrin, inhibit caspase-1 
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function, either by interference of caspase-1 recruitment to the inflammasome or 
through direct inhibition of caspase-1 activity (Lee et al., 2001; Lamkanfi et al., 2004; 
Humke et al., 2000; Chae et al., 2006).  Recent findings describe a role for NOD 
proteins in this two-step model, as MDP-induced IL-1β release is dependent on both 
NOD2 and NALP3, although the exact modalities of this synergy are yet to be 
unravelled (Pan et al., 2007).  
 
 
 
 
Fig.5: Inflammasome mediated IL-1β release. At least two disctinct stimuli are required for 
efficient IL-1β secretion. At first, an extracellular stimulus results in the expression of pro-IL-
1β, a proces often mediated by TLR ligands. Next, an intracellular DAMP activates the 
inflammasome and induces K+ efflux, resulting in the maturation and secretion of IL-1β.    
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3. Other NLRs 
 
Genetic studies using the A/J mouse strain revealed the importance of neural 
apoptosis inhibitory protein 5 (NAIP5, also called birc1e) in pathogen clearance. 
Polymorphisms in the NAIP5 locus of these mice results in a greater susceptible to 
Legionella pneumophila infection (Wright et al., 2003; Diez et al., 2003). Recently it 
was shown that NAIP5 recognises flagellin, resulting in the induction of caspase-1-
dependent cell death in macrophages (Molofsky et al., 2006; Ren et al., 2006; 
Zamboni et al., 2006).  In addition, IL-1β converting enzyme (ICE) protease activating 
factor (IPAF) is also required for Legionella pneumophila growth restriction. NAIP5 
and IPAF physically interact, supporting the hypothesis that NAIP5/IPAF cooperate in 
a complex (Zamboni et al., 2006).  The observation that IL-1β release but not 
bacterial growth is impaired in Asc-deficient macrophages following Legionella 
infection, reveals an unique function of the NAIP5/IPAF complex in pathogen 
clearance, but the exact modalities remain to be elucidated (Zamboni et al., 2006; 
Mariathasan et al., 2004).   
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Scope of the thesis 
 
 
 
The Toll-Like receptor family is an essential component of the vertebrate 
innate immune system. Not only are TLRs important in the activation of innate 
immune cells like macrophages and neutrophils, but TLR signalling also activates 
and shapes the subsequent antigen-specific adaptive response. The clinical 
importance of TLRs is reflected by a number of disease states associated with 
aberrant TLR signalling including endotoxic shock, bacterial sepsis and autoimmune 
diseases like systemic lupus erythematosus. Thus, TLR activation is a double-edged 
sword, balancing between effective pathogen clearance and excessive inflammation. 
Therefore, several mechanisms have evolved that dampen TLR responses, 
preventing prolonged and harmful inflammation.  TLR signalling is attenuated either 
by preventing ligand binding, by downmodulation of TLR expression or by inhibition 
of downstream signalling. The cardinal role of TLRs in mammalian innate immunity 
makes of them valuable therapeutic targets. Currently, TLR agonists as well as TLR 
antagonists are tested for their therapeutic potential in cancer, infections, allergic and 
autoimmune diseases.   
 
  The MAPPIT system is a mammalian two-hybrid technique that was 
developed in our laboratory. Its mammalian context is a major asset for unravelling 
signalling pathways as reflected by several studies on different type I cytokine 
receptors. Several aspects of erythropoietin, leptin and growth hormone receptor 
signalling pathway were successfully studied. The main objective of this thesis was 
the adaptation of the MAPPIT technique into a TLR context. This work mainly 
focuses on TLR adaptors and downstream kinases, which both are involved in the 
initial steps of TLR signalling.  Throughout this thesis we aimed at providing a better 
insight in the adaptor recruitment by various TLRs and as such provide a molecular 
basis for some questions raised by adaptor knock-out studies. In addition, the role for 
the SOCS protein CIS in TLR adaptor protein regulation was also assayed. The 
rationale of this research was the growing evidence that SOCS proteins are involved 
in negative regulation of TLR signalling. 
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Using MAPPIT we could demonstrate a ‘signalling interaction cascade’ from 
TLR4 to the downstream IRAK kinases (Part II, chapter 1). Moreover, we generated a 
TLR-adaptor interaction map (Part II, chapter 2). In that way, we could confirm 
several well-documented interactions and we also found some new interactions. We 
showed that MAPPIT can detect indirect associations and these MAPPIT data could 
be confirmed by coimmunoprecipitation studies (Part II, chapter 2). 
 
  Secondly, we identified CIS, a member of the SOCS protein family, as a 
MyD88-interacting protein (Part II, chapter 3). The role of SOCS proteins in 
attenuation of cytokine receptor signalling is well established and recently SOCS1 
was identified as a negative regulator of TLR signalling. Our data suggest a role for 
CIS in the regulation of MyD88-dependent signalling. We also observed a differential 
binding modus of CIS between cytokine receptor association and MyD88 interaction, 
reflected by a selective dependency of a conserved tyrosine in the SOCS-box 
domain of CIS. 
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PART 2: Results 
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CHAPTER 1: Mammalian protein-protein interaction Trap (MAPPIT) 
I. Tools to study Protein-Protein interactions 
 
Interactions between proteins form the basis of most cellular processes. 
Protein complexes can form stable structures such as ribosomes or the nuclear 
scaffold. However, a particular cellular context results in a different cellular response. 
The protein-protein interactions involved in the regulation and control of these cellular 
processes are therefore temporary and often dependent on the modification of one or 
more interaction partners.  
The generation of an interaction profile of a given protein substantially 
contributes to its functional characterisation in a particular cellular context. Therefore, 
a wide spectrum of both biochemical and genetic methods for studying protein 
complexes has been developed. Biochemical techniques rely on the co-purification 
and co-precipitation of interaction complexes. Classical examples are 
coimmunopreciptiation, chromatography-based methods and tandem affinity 
purification (TAP). The latter technique makes use of a bait protein linked to a dual 
affinity-tag. Following cellular expression of the bait protein, cell lysis and a two-stage 
purification step, protein complexes are separated by gel electrophoresis. 
Subsequent identification is based on mass spectrometry and database searches  
(Puig et al., 2001; Rigaut et al., 1999). TAP analysis has been successfully applied to 
purify yeast, plant as well as mammalian protein complexes (Gavin et al., 2006; 
Rohila et al., 2004; Bouwmeester et al., 2004). Over the years, several adaptations of 
the original protocol were described, which significantly improved identification 
efficiency either by optimizing the dual-affinity tag (Burckstummer et al., 2006) or by 
RNAi knockdown of the endogenous bait protein (Forler et al., 2003). A major asset 
of the technique is that it allows detection of protein complexes in whole. However, 
the indispensable lysis step can result in the loss of weak interactions. Moreover, this 
removal of proteins from their cellular environment allows interaction between 
differentially localised proteins, which could lead to a number of false positive 
interactions. 
 Genetic approaches rely on hybrid bait and prey molecules designed in such a 
way that their interaction leads to a detectable signal. The yeast two-hybrid method is 
based on reconstitution of a transcription factor (Fields and Song, 1989). Herein, bait 
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and prey are genetically fused to either the DNA-binding domain or the transcription 
activation domain of a transcription factor. Interaction of bait and prey restores 
transcriptional activity, resulting in the activation of a reporter gene.  The yeast-two 
hybrid system is the most widely used genetic assay to identify protein interactions 
and has been applied for high-throughput interaction mapping. A proteome-wide 
interactome has been accomplished for Saccharomyces cerevisiae (Ito et al., 2001), 
Drosophila melanogaster (Giot et al., 2003) and Caenorhabditis elegans (Reboul et 
al., 2003) and a human interaction map is underway (Rual et al., 2005; Stelzl et al., 
2005).  However, the technique suffers from some major draw-backs. Functional 
complementation is carried out in the nucleus. Hence, failure in nuclear localisation of 
either bait or prey results in false negatives. Moreover, the yeast environment is not 
favourable for interactions of higher eukaryotes, which often depend on post-
translational modifications. These limitations can in part be circumvented by the use 
of mammalian cell systems.  
In analogy with the original yeast protocol, the mammalian two-hybrid strategy 
is based on transcription factor complementation and accordingly is dependent on a 
nuclear localisation of bait and prey (Dang et al., 1991). In the past years several 
other mammalian systems have been described allowing detection of protein 
interactions in their natural environment. These methods include the mammalian Ras 
recruitment system, split-ubiquitin approaches, protein-splicing based assays, 
MAPPIT and reporter enzyme complementation systems (reviewed in Eyckerman 
and Tavernier, 2002; Lievens et al., 2006). In the latter technique, distinct non-
functional protein fragments of reporter enzymes like β-galactosidase, luciferase or 
dihydrofolate reductase, are fused to bait and prey. Upon bait-prey interaction, the 
reporter protein is reassembled, leading to its functional reconstitution. 
Some techniques can be used to visualize interactions in real time, of which 
fluorescence resonance energy transfer (FRET) and bimolecular fluorescence 
complementation (BiFC) are the principle ones (Jares-Erijman and Jovin, 2003; Hu et 
al., 2002). FRET detection is based on the energy transfer between two fluorophores 
that are brought in close proximity by association of the fused proteins, whereas BiFC 
depends on the formation of a bimolecular fluorescent complex, facilitated by the 
interaction of proteins linked to the non-fluorescent constituents of this complex. 
Mammalian Protein-Protein interaction Trap (MAPPIT) is a type I cytokine-
receptor based mammalian two-hybrid technique that was developed in our 
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laboratory (Eyckerman et al., 2001). The following section overviews the MAPPIT 
technique and its analytical application in TLR signalling.   
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Abstract 
 
 The mammalian protein-protein interaction trap (MAPPIT) is a two-hybrid 
technique founded on type I cytokine signal transduction. Thereby, bait and prey 
proteins are linked to signalling deficient cytokine receptor chimeras. Interaction of 
bait and prey and ligand stimulation restores functional JAK-STAT signalling, which 
ultimately leads to the transcription of a reporter or marker gene under the control of 
the STAT3-responsive rPAP1 promoter. In the subsequent protocol we describe the 
use of MAPPIT to study early events in TLR signalling. We here demonstrate a 
‘signalling interaction cascade’ from TLR4 to IRAK-1. 
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1. Introduction 
 
 
Monitoring interaction partners of a given protein is often a major step in 
revealing its biological role. Therefore, a wide spectrum of biochemical and genetic 
methods for studying protein-protein interactions has been developed. For a recent 
general review, we refer to Lievens et al. (1). The Mammalian Protein-Protein 
Interaction Trap (MAPPIT) (2) was used in this protocol to map TLR signalling from 
TLR4 to IRAK-1. MAPPIT is a two-hybrid assay based on type I cytokine signal 
transduction. Ligand-induced activation and reorganisation of type I cytokine 
receptors leads to cross-phophorylation and activation of receptor-associated 
cytosolic Janus Kinases (JAKs). Subsequently, these activated JAKs phosphorylate 
conserved tyrosine motifs in the cytoplasmic tail of the receptor, which become 
docking sites for signalling molecules like Signal Transducers and Activators of 
Transcription (STATs). Upon recruitment, STATs are phosphorylated by the JAKs and 
those activated STATs translocate as dimers to the nucleus, where they induce 
specific gene transcription (Fig 1A).  In MAPPIT, a C-terminal fusion of a given ‘bait’ 
protein with a leptin receptor that is deficient in STAT3 recruitment is made. The 
‘prey’ protein on the other hand is linked to a series of 4 functional STAT3 
recruitment sites of the gp130 chain. Association of bait and prey and ligand 
stimulation leads to phosphorylation of the prey chimeras resulting in STAT3 
recruitment, activation and translocation to the nucleus leading to induction of a 
STAT3–responsive luciferase reporter (rPAPI-Luci) (Fig 1B). 
The mammalian cell context of the assay is a major asset compared to the 
classical yeast-two hybrid method. This near-optimal physiological environment 
encompasses the need for posttranscriptional modification, often crucial in 
mammalian protein-protein interactions. For example, JAK2 target sites in the bait 
protein were found to be phosphorylated upon receptor activation, further 
underscoring the relevance of using MAPPIT to study signalling pathways. Serine 
phosphorylation-dependent interactions could also readily be detected using 
heteromeric MAPPIT (3), whereby kinase and substrate were fused to one of both 
heteromeric receptor chains.  
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Intrinsic to the MAPPIT setup, interactor and effector zones are physically 
separated respectively in the cytosol and the nucleus since signal readout is 
mediated by endogenous STAT molecules. In that way, direct interference of bait 
and prey chimeras with transcription of the reporter gene is avoided.  Moreover, 
signals are cytokine-stimulation dependent, allowing us to discriminate for ligand-
independent false positives.   
 
 
 
 
 
 
 
Figure 1: 
(A) Schematic overview of the JAK-STAT signal transduction pathway (see main text). L, Ligand. SRE, 
STAT-responsive element. 
(B) MAPPIT principle. A given ‘bait’ is C-terminally fused with a leptin receptor that is deficient in 
STAT3 recruitment. The extracellular domain of either the erythropoietin (EpoR) or of the leptin 
receptor (LR) can be used.  The ‘prey’ protein is linked to a series of 6 functional STAT3 recruitment 
sites of the gp130 chain. Association of bait and prey and ligand stimulation leads to STAT3 activation 
and induction of a STAT3–responsive luciferase reporter (rPAPI-Luci).   
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The potency of the analytical use of the MAPPIT technology is reflected by a 
growing number of studies on different type I cytokine receptors.  For instance,  
aspects of erythropoietin (4), leptin (5;6) and growth hormone (7) receptor signalling 
have been extensively studied.  Next to these type I cytokine receptors, this method 
can also be used to study some aspects of Toll-Like Receptor signalling (8), as 
described in this protocol.  
Based on this MAPPIT technology, a reverse two hybrid system has been 
developed (reverse MAPPIT) (9), which allows relatively easy discovery and analysis 
of disruptor molecules. Using reverse MAPPIT in a TLR context could lead to the 
development of therapeutics alleviating the consequences of uncontrolled TLR 
stimulation like excessive inflammation, autoimmunity and septic shock. 
 
2. Materials 
 
2.1 MAPPIT vectors 
 
1. pXP2d2-rPAP1-luci (pXP2d2 is a gift from Dr. S. Nordeen, Colorado Health 
Sciences Center, Department of Pathology, Denver, CO, 80262, USA, 
steve.nordeen@uchsc.edu). 
2. pCEL4f, pCLL2f (derived from pcDNA5/FRT vector; Flp-In System, Invitrogen) 
and pMG2 vectors (derived from pMet7 (2)). 
 
2.2 Analytical Application of MAPPIT 
 
2.2.1 Seeding of cells. 
 
1. Hek293T cell line (available from ATCC). 
2. Growth medium: Dulbecco’s modified Eagle’s medium (DMEM) supplemented 
with 10% Fetal Calf Serum 
3. Gentamycin and Penicillin/Streptomycin Solution (Invitrogen). 
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2.2.2 Transient Ca3 (PO4)2 transfection of Hek293T cells.  
 
1. 2.5M CaCl2. Prepare in dH2O. Filter sterilize by passage through a 0.45 µM 
nitrocellulose membrane and store at -20 °C. 
2. 2x Hepes-Buffered Saline (HeBS): 280 mM NaCl, 1.5 mM Na2HPO4, 50mM 
HEPES. Adjust pH to 7.05 with NaOH. Filter sterilize by passage through a 
0.45 µM nitrocellulose membrane and store at -20 °C. 
 
2.2.3 Cell Transfer and Stimulation   
4. Ca2+- and Mg2+-free Phosphate Buffered Saline (Invitrogen) and Cell 
dissociation agent (Invitrogen). 
5. Mouse leptin (R&D systems). Dilute to 20µg/ml in growth medium. Store 
aliquots at -20°C. 
 
2.2.4 Luciferase Reporter Gene Assays  
 
1. Cell culture lysis reagent: 25 mM Tris-phosphate (pH 7,8), 2 mM DTT, 2 mM 2,2 
diaminocyclohexane-N,N,N’,N’-tetra-acetate (DCTA), 10% glycerol, 1% Triton X-
100. 
2. Luciferase substrate: 20mM Tricine,  1.07 mM (MgCO3)4Mg(OH)2.5H2O, 2.67 
mM MgSO4 , 33.3 mM DTT, 0.1 mM EDTA, 270 µM CoA, 530 µM ATP, 470 µM 
D-Luciferin. 
3. Luminescence counter (e.g. Topcount, Packard). 
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2.3 Assaying prey expression 
 
1. Modified RIPA lysis buffer: 200 mM NaCl, 50 mM Tris-HCl (pH 8), 0.05% SDS, 
2 mM EDTA, 1% NP40, 0.5%  Desoxycholate, 1 mM NaVanadate, 1 mM NaF, 
20 mM b-glycerophosphate. Prepare 50 ml in dH2O. Add 1 tablet of Complete® 
proteinase inhibitor cocktail just prior to use. Store at 4°C. 
2. Separating buffer: 1.5 M Tris-HCl, pH 8.8, 0.1% SDS. 
3. Stacking buffer: 0.5 M Tris-HCl, pH 6.8, 0.1% SDS. 
4. Thirty percent acrylamide/bis solution (29:1) (Bio-Rad) (caution: this agent is 
a neurotoxin when unpolymerized). 
5. N,N,N’,N’-Tetramethyl-ethylenediamine (TEMED, Bio-Rad). 
6. Ammonium persulfate (10% solution). 
7. Prestained molecular weight marker (e.g. All Blue Standards, Biorad). 
8. Running buffer (5X): 125 mM Tris, 960 mM glycine, 0.5% (w/v) SDS.  
9. Loading Buffer (2X): 5% beta-mercaptoethanol, 2% SDS, 8% glycerol, 62 mM 
Tris-HCL pH 6.8, 1% Bromine-phenolblue. 
10. Nitrocellulose membrane (e.g. Hybond-C , Amersham Biosciences) and 3MM  
Whatman paper. 
11. Transfer Buffer: 25 mM Tris base, 0.2 M Glycine, 20% Methanol.  
12. 10X Tris-Buffered Saline (TBS): 0.2 M Tris-HCl, 1.37 M NaCl. Adjust pH to 7.6 
with HCl. 
13. Wash Buffer (1X TBS-T): 1X TBS, 0.1% Tween-20.  
14. Blocking  Buffer (LI-COR® Biosciences). 
15. Antibody dilution buffer: Blocking  Buffer (LI-COR® Biosciences), 0.1% Tween-
20. 
16. Primary antibody: anti-Flag M2 (Sigma). 
17. Secundary antibody: goat anti-mouse IRDye® 680 or 800CW (LI-COR® 
Biosciences). 
18. Odyssey® infrared imaging system (LI-COR® Biosciences). 
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3. Methods 
 
The standard MAPPIT assay makes use of the human embryonic 293T (HEK293T) 
cells. Other cells lines can also be used. Examples include the haematopoietic TF1 
(10) and the neuronal N38 cell lines (Wauman et al., submitted). Briefly, the cells are 
transfected with the bait plasmid, the prey plasmid and a STAT-dependent reporter 
gene (pXP2d2-rPAP1-luci). The stimulation of the reporter gene is used as a measure 
of the interaction between the bait and prey proteins.  
To study TLR signalling using MAPPIT we cloned the intracellular part of some 
TLRs as a bait and TLR adaptors and downstream signalling molecules both as bait 
and prey.  As proof-of-principle we studied the signalling cascade starting from TLR4. 
Tested interactions are depicted in Figure 2 (see Note 1).  
 
 
 
 
Figure 2: Initial steps in TLR4 signalling. All tested MAPPIT interactions, as shown in Figure 3, 
are annotated with an encircled capital.  
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We first examined the adaptor recruitment by TLR4, using the intracellular 
part of TLR4 as bait (TLR4ic) and different adaptors as prey (Fig 3A).  Clear 
interaction could be detected between TLR4ic and Tram or Mal. However, co-
transfection of the TLR4ic bait and the MyD88-prey did not lead to any luciferase 
induction, although the role of MyD88 in TLR4 signalling is well documented (11). 
We therefore examined if this interaction could be indirect. When co-transfecting a 
Mal expression vector together with TLR4ic-bait and MyD88-prey, a clear MAPPIT 
signal was detected, indicating that Mal bridges MyD88 to TLR4. These data are 
consistent with the phenotype of Mal-deficient mice, which is analogous to MyD88-
deficient mice in terms of TLR2 and TLR4 signalling (12),  and with a recent report, 
describing delivery of MyD88 to TLR4 as the primary function of Mal (13). These data 
prove that indirect interactions can be detected using the MAPPIT assay. 
As expected, heterodimerisation of Mal and MyD88 was readily detected in a 
reciprocal way, using these adaptors either as bait or prey (Fig 3B).  Further 
downstream, the interaction of MyD88 and IRAK-4 was also observed (Fig 3C) and 
association of Mal with IRAK-4 was strongly increased upon MyD88 co-expression, in 
analogy with the indirect TLR4-MyD88 binding (Fig 3C, lower panel). Finally, 
dimerisation of IRAK-1 and IRAK-4 could be demonstrated (Fig 3D). Taken together, 
these data illustrate that MAPPIT can be used to walk down the TLR signalling 
pathway from the receptor to the downstream IRAK kinases. MAPPIT thus provides a 
unique tool to study these molecular interactions in great detail in intact mammalian 
cells.  
The design of prey and bait vectors and a typical protocol for an analytical 
MAPPIT assay are described below. 
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Figure 3: (A) Adaptor recruitment by TLR4.  Hek293T cells were transiently co-transfected with the 
MAPPIT bait plasmid pCLL-TLR4ic, various TLR-adaptor prey constructs (or a SVT-prey as negative 
control (see Note 6)), and the STAT3-responsive rPAPI-luci reporter. The effect of Mal expression on 
MyD88 association was assayed by co-transfection of a Mal expression vector (pcDNA5-Mal). Twenty-
four hours after transfection the transfected cells were stimulated with leptin (100 ng/ml) for another 
24 h or were left untreated (NS). Luciferase measurements were performed in triplicate. Data are 
expressed as mean fold induction (ratio Stimulated/NS). 
(B) Heterodimerisation of Mal and MyD88. Hek293T cells were transiently co-transfected with the 
MAPPIT bait plasmid pCLL-Mal and the prey vector pMG2-MyD88 (upper panel) or the reciprocal 
situation (lower panel) together with the rPAPI-luci reporter. Experimental setup was as in (A). 
(C) MyD88 and IRAK-4 association. Interaction of MyD88 and IRAK-4 was assayed using the MyD88-
bait plasmid pCLL-MyD88 and the pMG2-IRAK4 prey vector (upper panel) or with the reciprocal setup 
(lower panel). Indirect association of Mal and IRAK-4 was demonstrated by co-transfecting a MyD88 
expression vector (pMet7-MyD88) (lower panel). Experimental setup was as in (A). 
(D) Dimerisation of IRAK-1 and IRAK-4. Using IRAK-4 as a bait (pCLL-IRAK-4) and IRAK-1 as a prey 
(pMG2-IRAK-1), heterodimerisation of both kinases was monitored. Experimental setup was as in (A). 
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3.1 MAPPIT vectors 
 
The plasmid vectors pMG2, pCEL4f and pCLL2f were developed for analytical 
MAPPIT applications. The structure of these vectors and of the protein chimeras they 
encode is shown in Figure 4. Subcloning is performed using standard methods.  
The protein used as a prey is cloned C-terminal to the gp130 fragment. The pMG2 
plasmid is derived from the mammalian expression vector pMET7, which contains the 
strong SRα promoter. This vector encodes the FLAG-tagged gp130 fragment (aa 
760-918), of which aa 905-918 were duplicated, with a glycine-glycine-serine (GGS) 
amino acid linker region preceding the stuffer. 
To exchange the stuffer with the prey-encoding sequence the following 
restriction sites can be used: EcoRI in combination with NotI, XhoI or XbaI (Fig. 4A). 
The pCEL4f and pCLL2f vectors express the receptor-bait chimera. Both vectors 
originate from the pcDNA5-FRT plasmid (Flp-In system, Invitrogen). Bait expression 
is controlled by the human cytomegalovirus (CMV) promoter. The extracellular 
portion of either the human erythropoietin receptor (EpoR, pCel4f) or the murine 
leptin receptor (LR, pCLL2f) is used (see Note 2).  Transmembranary and 
intracellularly, both bait-chimeras consist of the LR in which conserved tyrosine 
residues have been mutated to phenylalanine (LR-F3). Bait proteins can be cloned 
after the C-terminal GGS hinge sequence using SacI or BamHI and NotI restriction 
sites (Fig.4B). These vectors also contain a Flp Recombination Target (FRT) site 
followed by a hygromycin resistance cassette to permit Flp recombinase-mediated 
integration in suited cell types (Invitrogen).  
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Figure 4: Diagrammic presentation of vectors used in an analytical MAPPIT approach.  
(A) The pMG2 vector is used to express the prey. An N-terminal flag-tag was added to check for prey 
expression, which is controlled by the strong SRα promoter. The pMG2 vector contains aa 760-918 of 
the gp130 chain, of which aa 905-918 were duplicated. 
(B) The pCEL4f and pCLL2f vectors encode the chimeric bait receptor under control of the CMV 
promoter. pCEL4f and pCLL2f contain the extracellular domains of the EpoR or LepR, respectively. 
Both vectors contain a FRT sequence which can be used for recombination-assisted integration into 
the genome of suited cell lines, e.g. T-Rex cell lines (Invitrogen). 
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3.2  Analytical Application of MAPPIT 
  
3.2.1 Seeding of cells. 
 
1. For each tested condition, plate 4 × 105 subconfluent HEK293T cells in one 10-
cm2 well (6-well plate). Sufficient cells should be plated to allow the 
experiments to be performed in triplicate and to monitor expression of the bait 
and prey proteins. 
2. Grow overnight in a humidified atmosphere at 37°C and 8 to 10 % CO2. 
 
3.2.2 Transient Ca3 (PO4)2 transfection of Hek293T cells.  
 
1. For each well make a DNA/CaCl2 mixture containing 0.5 µg of pCLL2f bait 
construct, 0.5 µg of pMG2 prey construct, 200 ng pXP2d2-rPAP1-luci and 15 µl 
2.5 M CaCl2 in a total volume of 150 µl dH2O in a 1.5-ml tube (see  Note 3). 
Gently drop 125 µl of the DNA mixture into 125 µl 2× HeBS solution  in a 1.5-
ml tube, while vortexing 
2. After vortexing the mixture for 5 additional seconds, leave precipitation 
mixture for 10-20 minutes at room temperature (see Note 4).  
3. Add the precipitation mixture to one of the wells of a 6-well plate containing 
the HEK293T cells. 
4. Leave precipitate on cells overnight in the incubator. 
5. Remove medium and wash cells once with 1 ml PBS (see Note 5). 
6. Add 2 ml fresh growth medium 
7. Incubate the cells for 8 hours in a humidified atmosphere at 37°C and 8 to 10 
% CO2. 
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3.2.3 Cell Transfer and Stimulation 
 
1. Remove the Growth Medium and wash once with 1 ml PBS  
2. Add 200 µl Cell Dissociation Agent to each well and incubate for 5 minutes. 
3. Gently tap plate to detach all cells. 
4. Add 2 ml Growth Medium and triturate using a 1 ml pipette to break cell 
clusters. 
5. Plate 50 µl of cell suspension in a black-well plate. We recommend 3 wells for 
every stimulation condition. The remainder of the cells are left in the 6-well 
and can be used for Western blot analysis to verify prey expression (see 3.3). 
6. Add 50 µl Growth Medium or 50 µl Growth Medium containing leptin to each 
well of the black-well plate. Final leptin concentration should be 100 ng/ml. 
7. Grow both the black-well plate and the 6-well plate with the remainder of the 
cells overnight in a humidified atmosphere at 37°C and 8 to 10 % CO2. 
 
 
3.2.4 Luciferase Reporter Gene Assays  
 
1. Remove growth medium from the black 96-well plates.  
2. Add 50 µl of cell culture lysis reagent to each well and incubate for 15 
minutes. At this time point, plates can be stored at -20°C. 
3. Add 35 µl of luciferase substrate to each well and instantly measure the plate 
in a luminescence counter. 
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3.3 Assaying prey expression. 
 
For a correct analysis of the data generated with the MAPPIT technique, the 
expression of the prey chimera should be assayed. Using standard SDS-PAGE and 
Western Blotting techniques, prey expression can be checked using the N-
terminal flag-tag present on every prey. 
 
1. Discard Growth medium of the remainder of the transfected cells in the 6-well 
plate (after 3.2.3) and wash once with 1 mL PBS. 
2. Add 150µl modified RIPA to each well and incubate on ice for 5 minutes. 
3. Transfer lysates into a 1.5 mL tube and centrifuge at full speed to pellet the 
nuclei. 
4. Use 15 µl of the supernatant and add 15  µl 2x loadingbuffer. 
5. Boil samples for 5 minutes. 
6. After cooling down to room temperature, samples are ready for SDS-PAGE. 
7. Load samples on a 1.5 mm thick, 10 % polyacrylamide gel. The gel can be run 
at 80V through the stacking gel and at 120V through the separating gel until 
the dye fronts run off the gel. 
8. Next, the separated samples are transferred to a nitrocellulose membrane 
electrophoretically. Transfer can be obtained at 120V for 1.5 hour or overnight 
at 30V. 
9.  After transfer, the membrane is incubated in 10 mL blocking buffer for 1 hour 
at 4°C on a rocking platform. 
10.  The blocking buffer is discarded and a 1:4000 dilution of the anti-Flag 
antibody (Sigma) is administered. Incubate for 1 hour at 4°C on a rocking 
platform. 
11. Discard the primary antibody and wash the membrane 5 times for 5 min each 
with 10 mL TBS-T. 
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12.  Incubate the membrane for another hour with a 1:5000 dilution of the 
secondary antibody. 
13.  Discard the secundary antibody and wash the membrane 5 times for 5 min 
each with 10 mL TBS-T. 
14. Once the final wash is removed from the blot it can be stored at -20°C or 
scanned directly for prey expression with the Odyssey® infrared imaging 
system (LI-COR® Biosciences) 
 
4.  Notes 
 
1. No MAPPIT signals were detected using Trif as bait or as prey. Expression of 
the Trif-prey was limited to a perinuclear compartment. Since MAPPIT 
measures interactions in the sub-membranary space, this finding provides a 
likely explanation for the lack of Trif-dependent signals in MAPPIT 
experiments. Of note, mutagenesis studies in conjunction with the MAPPIT 
read-out and immunofluorescence studies can be used to identify the 
localisation signals involved in targeting Trif to this cellular subcompartment.  
2. Generally, a stronger signal is obtained when using the extracellular part of 
the LR, which can be explained by the fact that after binding of its ligand the 
LR undergoes higher order clustering, while the EpoR forms homodimers. 
Throughout this protocol only the pCLL-2f vector is used. 
3. Different ratios of bait and prey plasmids may yield better results in some 
settings. 
4. Do not let the mixture incubate much longer since this will reduce the 
transfection efficiency. The precipitate can be checked microscopically; the 
particles should look like small speckles (almost invisible at a 100× 
magnification) to obtain optimal transfection efficiencies. 
5. Do not leave the PBS too long on the cells since this can cause detachment. 
6. The pMG2-SVT vector is routinely used as a negative control. This vector 
encodes for a SV40 large T prey which lacks its nuclear localisation signal. Bait 
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expression can be monitored by using a prey capable of interacting with the 
LR-F3 portion of the bait, e.g. the SH2β-prey (data not shown). 
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CHAPTER 2: MAPPIT analysis of TLR adaptor complexes 
  
  
In this article we used the MAPPIT technique described in chapter 1 to study 
early events in TLR signalling. We cloned the intracellular part of some TLRs as bait 
and the TLR adaptor proteins both as bait and as prey. In this way, we generated a 
partial TLR-adaptor interaction map. The relevance of using MAPPIT to study TLR 
signalling was reflected by the ligand-independent activation of NF-κB following 
overexpression of the MyD88- or Mal-bait, indicating that MAPPIT allows the 
formation of functional signalling complexes at the cell membrane. Several known 
interactions could be confirmed including Tram or Mal association with TLR4 and 
homo-and heterodimerisation of Mal and MyD88. However, no interactions with the 
adaptor molecule Trif could be observed, possibly due to its perinuclear expression 
pattern. Also new interactions were found like the association of the TIR domain of 
Sarm with MyD88 and Tram. Using MAPPIT we could also show an indirect binding 
of MyD88 and TLR4 or TLR2. These interactions are mediated by Mal, consistent 
with the recent definition of Mal as a bridging adaptor, linking MyD88 to the activated 
TLR4 (Kagan and Medzhitov, 2006). These data were confirmed by 
coimmunoprecipitation. In addition, the dimerisation properties of MyD88 and Mal 
and the relative contribution of each of their subdomains in this process were further 
evaluated. 
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CHAPTER 3: The C-terminus of CIS defines its interaction pattern 
 
 
Members of the SOCS proteins are rapidly induced upon cytokine receptor 
and TLR activation and function as negative regulators of the aforementioned 
signalling pathways. These SOCS proteins are composed of a pre-SH2, a SH2 and a 
SOCS-box domain. In this study we evaluated the interaction profile of CIS, SOCS1, 
SOCS2 and SOCS3. By means of MAPPIT analysis, we could demonstrate that, 
besides the SH2-domain, the SOCS box of CIS is also essential for leptin receptor 
binding. Mutagenesis revealed that the conserved tyrosine Y253 in the C-terminus of 
the CIS SOCS-box is indispensable for receptor association. This C-terminal tyrosine 
is also critical for interaction with the Epo receptor, as demonstrated by both MAPPIT 
as well as peptide affinity chromatography experiments. Moreover, mutation of this 
tyrosine abolished the inhibitory function of CIS in Epo receptor signalling. 
Conversely, the interaction of CIS and the universal TLR adaptor MyD88 was 
not dependent on this conserved tyrosine. Further MAPPIT and 
coimmunoprecipitation experiments revealed that CIS interacts with the N-terminal 
death domain of MyD88. 
Finally, we could demonstrate that the SOCS-boxes of SOCS1, SOCS2 and 
SOCS3 are not essential for cytokine receptor association. 
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Interactions between proteins are essential in almost all cellular processes. 
Proteins can form stable structures including the proteasome complex, ribosomes 
and the cytoskeleton. However, protein interactions are also involved in the 
regulation of cellular responses. As these processes are context-dependent, the 
protein complexes involved are often of a temporary nature. Identification of 
interactors of a protein in a given cellular context, can contribute considerably to its 
functional definition.    
As discussed in chapter 4, a wide spectrum of biochemical and genetic 
techniques have been developed to study these protein-protein interactions.  
Biochemical techniques have the advantage that signalling complexes can be 
analysed in whole. However, the lysis step involved in these methods can lead to a 
loss of weak interactions. Moreover, cell lysis disrupts the normal cellular 
environment, which can result in false positive interactions between proteins normally 
residing in separate cellular compartments. Genetic methods rely on hybrid bait and 
prey molecules, of which interaction lead to detectable signals. The frequently used 
yeast two-hybrid method is based on functional complementation of a transcription 
factor (Fields and Song, 1989). However, this technique suffers from some intrinsic 
drawbacks. Bait and prey interaction need to occur in the nucleus, thus excluding the 
analysis membrane-bound proteins. Moreover, interactions between mammalian 
proteins often require post-translational modifications, which are hard to reproduce in 
a yeast context.  
 To circumvent these restrictions, MAPPIT was developed in our laboratory 
(Eyckerman et al., 2001). The MAPPIT system relies on the fundaments of type I 
cytokine signalling, exploiting the cardinal JAK/STAT signalling pathway. Interaction 
of bait- and prey-hybrids leads to the functional complementation of a STAT3 
recruitment-deficient leptin receptor by STAT3 recruitment sites on the gp130 chain. 
Next to the advantages intrinsic to its mammalian context, MAPPIT disposes of some 
additional assets. Since signal readout is mediated by STAT molecules, commuting 
between cytosol and nucleus, nuclear translocation of bait and prey molecules is 
avoided. Moreover, these bait and prey proteins cannot directly interfere with signal 
readout. The versatile MAPPIT system appeared to be a valuable technique for the 
analysis of various signalling pathways including erythropoietin (Montoye et al., 
2005), leptin (Lavens et al., 2006); Wauman et al., submitted) and growth hormone 
receptor signalling (Lavens et al., 2006; Uyttendaele et al., 2007). The flexibility of the 
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MAPPIT system is also reflected by a number of reports where the technique has 
been applied in haematopoietic (Montoye et al., 2006) and neuronal (Wauman et al., 
submitted) cell lines. Other cell types can be used, on the condition that these cells 
endogenously express STAT3. Moreover, STAT5 expressing cells can also be used 
through the application of the βcommon-MAPPIT variant (Montoye et al., 2006). 
 
The MAPPIT system can also be used to screen for new interactors (Lievens 
et al., 2004). Therefore the luciferase reporter is changed by a surface tag, which is 
used as a selectable marker gene. Cells expressing a bait-interacting prey are 
enriched through a series of selection steps using magnetic-activated cell sorting and 
next selected by fluorescence-activated cell sorting (FACS). Ultimately, these positive 
cells are deposited as single cells, allowing easy identification of the bait-interacting 
proteins. 
 
Throughout this thesis, the MAPPIT technology was extensively used to study 
TLR signalling events. In that way we generated a TLR-adaptor interaction map. Both 
well-documented and new interactions could be detected. The strength of the 
MAPPIT technology was underscored by the observation that Mal acts as a bridging 
molecule, linking MyD88 to the activated TLR4, thereby demonstrating the potency of 
MAPPIT to detect indirect interactions. Our data are in line with a recent report, 
describing  the essential role of a PIP2 binding domain in the N-terminus of Mal in 
TLR4 signalling (Kagan and Medzhitov, 2006). This domain ensures Mal recruitment 
to PIP2-rich areas in the plasma membrane and was shown to be crucial in 
facilitating MyD88 delivery to an activated TLR4. Quite surprisingly, we could not 
detect direct interaction between MyD88 and other TLRs including TLR5, TLR7 and 
TLR9 using MAPPIT. Consistently, yeast-two hybrid methods also fail to demonstrate 
interaction between MyD88 and TLR9 (Brown et al., 2006). Moreover, MyD88 should 
be recruited to different subcellular compartments, as it is used by both endosomal 
as membrane expressed TLRs. The mechanisms involved in this differential 
translocation remain to be unravelled. Although we cannot exclude that the MAPPIT 
system fails to detect these interactions, these findings suggest that TLR5/7/9 use 
accessory molecules, with an analogous role as Tram and Mal in TLR4 signalling.  
In addition, we evaluated the homo-and heterodimerisation properties of Mal 
and MyD88. Moreover, analogous mutations as the TLR4P712H mutation in the BB 
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loop of the TLR4 TIR domain were made for Mal and MyD88, a mutation which is 
known to abrogate TLR4 signalling (Poltorak et al., 1998). These mutated adaptors 
failed to homo- and heterodimerise and also TLR interaction was abrogated. In that 
way we provided biochemical evidence for the observed signalling defects. These 
initial data prompt us to further characterise the TIR-TIR interaction surface using 
MAPPIT, through the evaluation of additional TIR domain mutations. 
 
TLR signalling balances on a tight rope, balancing between a potent immune 
response and excessive inflammation. Therefore, the TLR pathway is strictly 
controlled by various means. Inhibition of TLR signalling is achieved either by 
inhibiting ligand binding, by modulating TLR expression or by interfering in the 
intracellular signalling pathways. One group of intracellular TLR regulators is the 
SOCS protein family. The inhibitory function of SOCS1 in TLR4 signalling is well 
established, targeting the adaptor protein Mal for proteasomal degradation (Kinjyo et 
al., 2002; Nakagawa et al., 2002; Mansell et al., 2006). Using MAPPIT, we could 
demonstrate interaction between another member of the SOCS family, CIS, and the 
universal TLR adaptor MyD88. These finding suggest a regulatory role for CIS 
analogous to SOCS-1. However, functional data supporting this hypothesis remain to 
be found. This interaction was, much in contrast with interaction of CIS with the epo 
and leptin receptor, not dependent on a conserved tyrosine in the SOCS box domain 
of CIS. These findings suggest a differential interaction modus of CIS between 
receptor binding and recruitment of MyD88. SOCS proteins are subjected to tyrosine 
phosphorylation (Cacalano et al., 2001) and therefore, it is tempting to speculate that 
the critical tyrosine in the CIS SOCS-box needs to be phosphorylated to allow 
receptor interaction. Moreover, the corresponding tyrosine in the SOCS-box of 
SOCS3 was shown to be phosphorylated and this event was crucial for elongin C 
recruitment (Haan et al., 2003). Metabolic labelling experiments indicated that CIS 
can be phosphorylated. Moreover, an altered distribution of the tyrosine mutated CIS 
compared with the wild type was observed using 2D gel electrophoresis. However, 
future effort will need to clarify the nature and location of these modifications, which is 
essential to provide mechanistic insight of CIS interactions.   
 
The dramatic consequences of several autoimmune diseases, chronic 
inflammation and bacterial sepsis can be conferred to uncontrolled TLR signalling. 
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Because of their specific role in the signalling pathway, TLR adaptor molecules are 
considered as ideal therapeutical targets. Another MAPPIT variant, reverse MAPPIT, 
allows relatively easy discovery and analysis of disruptor molecules (Eyckerman et 
al., 2005). Using reverse MAPPIT in a TLR context, could lead to the identification of 
therapeutics disrupting the TIR-TIR interaction and in that way alleviating the harmful 
effects of inappropriate TLR signalling. Moreover, mutational studies using MAPPIT 
could provide a better insight in the nature of the TIR-TIR interaction surface, which 
will considerably facilitate therapeutic development. 
 
Taken together, our data prove the functionality of the MAPPIT system in a 
TLR framework. The MAPPIT toolbox can contribute substantially to the 
characterisation of TLR signalling pathways both by the analytical use of MAPPIT as 
well as by the FACS-based screening method. Moreover, the reverse MAPPIT 
methology appears to be a valuable tool for the screening of drugs inhibiting 
uncontrolled and harmful TLR signalling.  
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